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ABSTRACT 
 
Herpes simplex virus (HSV) infection of the cornea leads to a blinding immuno-
inflammatory condition of the eye also called stromal keratitis (SK). SK 
immunopathology is characterized by the infiltration of CD4+ T cells of Th1 phenotype 
as well as the development of new blood vessels into the normally avascular cornea. 
Studies in mouse models of SK have firmly established the role of CD4+ T cells, and 
particularly of Th1 phenotype, as the principal mediators of SK immunopathology. 
However, with the recent discovery of IL-17A and Th17 cells, the role of this cytokine as 
well as Th17 cells remains to be further defined. Recently it was shown that the normal 
cornea expresses VEGF-A, however its biological activity is impeded by its binding to a 
soluble form of VEGF-A receptor-1 (sVEGFR-1). Past studies have implicated the role 
of vascular endothelial growth factor-A (VEGF-A) in HSV induced corneal angiogenesis, 
however the source of VEGF-A as well as molecular mechanisms, particularly in the 
context of VEGF-A/sVEGFR-1 balance during HSV infection, are poorly understood. 
The first part of this dissertation (I) reviews past literature on HSV induced 
corneal SK immunopathology. It focuses on the understanding of HSV-1 induced events 
that particularly results in corneal angiogenesis as well as tissue damage mediated by 
different type of cells as well as their secreted products. The next three parts (II-IV) focus 
on the mechanisms of HSV induced corneal angiogenesis as well as the relative role of 
Th1 and Th17 cells in SK immunopathology. Results in part II focuses on the relative 
role of IFN-γ/IL-17 as well as Th1/Th17 cells in HSV induced corneal 
immunopathology. The third section evaluate the significance of VEGF-A/sVEGFR-1 
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balance in HSV induced corneal neovascularization. Results in part IV focus on the role 
of IL-17A in altering the balance between VEGF-A and sVEGFR-1 post ocular HSV 
infection and subsequent corneal angiogenesis.  
Collectively these studies identified novel mechanisms by which HSV infection 
of the cornea leads to the development of angiogenesis as well as corneal tissue damage 
and subsequent SK immunopathology, the most common cause of infectious blindness in 
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HERPES SIMPLEX VIRUS-1 (HSV) and Ocular Immunopathology 
 
 Herpes viruses are highly successful pathogens owing to some of the mechanisms 
to resist removal from host once they have caused infection (1-4). The transmission of 
HSV infection occurs through intimate contact with mucosal surfaces or abraded skin and 
oropharyngeal mucosa is the most common site for HSV-1 infection (5). HSV-1 initially 
replicates at the site of primary infection in the epithelial layer, followed by retrograde 
migration of intact virions to the trigeminal ganglion (TG) where infection is maintained 
in a latent state (5-7). During latency, the production of new replication competent virus 
is usually absent, however, immune suppression of the host can result in reactivation of 
the virus from latently infected TG (2, 3). After reactivation, the virus generally migrates 
to the initial site of infection and can lead to development of a variety of immuno-
inflammatory reactions depending upon the site of recurrent infection (6, 7). When 
corneal epithelial cells are the site of infection, a chronic immuno-inflammatory 
condition may result, which is termed as herpetic stromal keratitis (SK) that can cause 
damage to normal vision (8).  
 SK is the commonest cause of infectious blindness in the Western World. 
According to a recent study it is estimated that in the USA 400,000 persons are affected 
with 20,000 new cases of SK occurring annually (4). In humans, SK usually occurs 
following the reactivation of the virus from TG (8). The human SK pathogenesis is very 
complex, but thought to represent a CD4+ T cell orchestrated inflammatory reaction (8).  
Most of our knowledge of various events of SK pathogenesis is based on studies on 
experimental SK in animal models, particularly using the immunocompetent mouse as a 
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host for primary infection (Fig 1.1) (9-11). In this model, CD4+ T cells primarily 
orchestrate the SK lesions, however the exact nature of epitopes for these cells is still 
unidentified (9-11). Characteristically, SK lesions are also marked by the development of 
pathological angiogenic responses in the cornea that can be extensive and further impair 
normal vision (4, 12). Thus the clinical phase of SK pathogenesis involves at least two 
significant events, the migration of CD4+ T cells in the corneal stroma and the 
development of new blood vessels in the normally avascular cornea (Fig 1.1, 1.2) 
  Currently, therapeutic intervention of SK usually involves a combination of anti-
viral and anti-inflammatory drugs (13-15). However, to control the perpetuating 
inflammatory reaction, long periods of anti-inflammatory drugs, particularly 
corticosteroids, are administered which can have serious side effects such as risk of 
cataract formation and glaucoma (13-15). Additionally, in some patients corticosteroids 
may promote HSV replication thereby worsening the SK lesion severity (16). Thus there 
is a need for the development of new and alternative therapeutic strategies to control SK. 
Understanding various molecular mechanisms responsible for development of complex 
SK lesion could shed light on possible targets for better control of SK pathology.   
 
Pathogenesis of SK 
 In the mouse model, primary ocular infection with HSV is followed by initial 
replication of virus in the corneal epithelium for up to 5-6 days (Fig 2) (4). Live viral 
particles, as well as transcribed mRNA copies of viral genes were detected from the 
corneal swabs during early time points up to day 7 post infection (pi). However, viral 
DNA was detected in the cornea up to day 21 pi when SK lesions were fully evident (4).  
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Early after HSV infection, a prominent infiltration of innate inflammatory cells, 
particularly neutrophils, occured in corneal stromal layer adjacent to infected corneal 
epithelial cells (17). Neutrophils primarily migrated from the limbal blood vessels 
conceivably in response to various chemokine signals released after initial virus infection 
(4, 17). Neutrophil influx was characterized by a biphasic response in which initial 
infiltration started around 18 hrs pi, peaked at day 2 pi followed by a decline reaching to 
undetectable levels around day 5 pi. A second wave of neutrophil infiltration started from 
day 7 pi that persisted throughout the course of the clinical phase of SK (4, 17, 18). 
Although, neutrophils initially played a protective role in the virus clearance (19), 
subsequently during the clinical phase of SK they contributed to the corneal tissue 
damage and angiogenesis (17, 18). Thus depletion of neutrophils during early stages of 
HSV infection with specific monoclonal antibody mAb led to higher viral titers as well as 
delayed clearance of virus from the cornea (19). However, depletion of neutrophils 
during the clinical phase of SK resulted in significantly diminished angiogenesis as well 
as reduced SK lesion severity (18). This reduced inflammatory condition post neutrophil 
depletion was the result of reduced levels of various molecules secreted by neutrophils, 
which contribute to the tissue damage. Neutrophils through their degranulation and 
release of various factors such as nitirci oxide (NO), matrix metalloproteinases (MMPs), 
VEGF-A, IL-1β, IL-8, IL-12 and TNF-α contributed to the ongoing inflammation and 
further tissue destruction which may unmask corneal auto-antigens (4, 20-24). VEGF-A 
and MMP-9 play an important role in HSV induced corneal neovascularization 
(described later) (18, 23).  
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 In addition to neutrophils, other innate immune cells such as DCs, NK cells, γδ-T 
cells and macrophages also participate in viral clearance and the subsequent 
inflammation by secreting various effector molecules such as type I IFNs, cytokines and 
chemokines (IL-17, IL-1β, IL-12, MIP-2 TNF-α, IFN-γ, IL-23) (4). Among these various 
cytokines, IL-1β and IL-6 were demonstrated to have a critical and central role in 
orchestrating the early inflammatory reaction (25-27). Although, after productive HSV 
infection of epithelial cells, most host gene expression is turned off (27), expression of 
pro-inflammatory cytokines such as IL-6 and IL-1β is increased at least for an initial 
period (day 1-2 post infection) and may represent a significant initial source of these 
cytokines (4, 27-29). Furthermore, uninfected corneal epithelial cells become the 
significant producers of IL-6 and IL-1β (4). However, it is still poorly understood how 
the uninfected corneal epithelial cells are programmed to produce these cytokines. One 
possible explanation for this is that pathogen associated molecular patterns (PAMPs) 
expressed by virus-infected cells or perhaps extracellular virus itself could activate 
various pattern recognition receptors. These include Toll-like receptors (TLR)-2, 4, and 9 
with subsequent activation of NFκB pathway causing them to synthesize and secrete 
cytokines (4, 30, 31). Evidence for this is that CpG motifs derived from viral DNA in the 
cornea could stimulate TLR-9 and induce IL-1β and IL-6 that act in a paracrine fashion 
on other cells and induce them to secrete various inflammatory mediators that contribute 
to the immunopathological lesion as well as induction of adaptive immune response (30, 
32, 33). Furthermore, IL-1β acts in a paracrine fashion on un-infected corneal epithelial 
cells and stimulates the production of IL-6 (34, 35). IL-6 triggers the synthesis of MIP-2 
(CXCL8), which is involved in neutrophil influx at the site of inflammation. In addition 
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to IL-1β and IL-6, TNF-α also plays an important role in SK pathogenesis, as indicated 
by studying SK pathogenesis in mice lacking TNF-α. These results showed that such 
mice were unable to control virus replication in the cornea and as a consequence 
exhibited an enhanced SK lesion severity (4, 34-37). Thus early events after HSV 
infection trigger the production of various cytokines and chemokines, which initiate the 
innate immune response and set the stage for further adaptive immune response as well as 
immunopathology.  
 
Is SK Immunopathology: Th1 or Th17 mediated? 
  
Early events of the innate immune response drive various critical events that 
ultimately result in the adaptive immune response.  IL-12 is another critical cytokine that 
is produced by neutrophils, macrophages and Langerhans DCs and plays an important 
role in SK pathogenesis (4, 38-40). IL-12 stimulates the production of IFN-γ by 
macrophages, NK cells, neutrophils as well as CD4+ T cells (40, 41). IFN-γ has been 
shown to exert both pro-inflammatory and anti-inflammatory activity (4). It promotes 
neutrophil infiltration at the site of inflammation through upregulation of PECAM-1 and 
ICAM-1 on corneal epithelial cells (42, 43). Studies in an animal model of SK have 
revealed a critical contribution of CD4+ T cells of the Th1 subset as principal 
orchestrators of SK lesions (44, 45).  However, the identity of target antigens that drive 
SK Th1 cells generation during SK immunopathology is poorly understood (4, 44, 45). It 
is anticipated that initial corneal infiltrating Th1 cells are HSV specific, however later on 
SK lesion would be dominated by bystander cell population (Ref).   
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Recent work has revealed the critical pro-inflammatory role of IL-17A in 
pathogenesis of many inflammatory and autoimmune diseases (46-48).  IL-17 mediates 
the local inflammatory response by stimulating epithelial, endothelial and fibroblastic 
cells and inducing the release of various inflammatory cytokines (49). IL-17A drives 
increased influx as well as survival of neutrophils at the site of inflammation by induction 
of neutrophil chemoattractant as well as GM-CSF mediated granulopoeisis (50, 51).  IL-
17A signals through a homodimeric IL-17A receptor A (IL-17RA), which is expressed 
ubiquitously, with higher levels in hematopoietic tissues (52, 53). Signaling through IL-
17RA activates both NFκB and Jnk kinase pathway, resulting in an increased expression 
as well as an improved mRNA stability of various pro-inflammatory cytokines (52, 53).  
In the beginning, IL-17A was thought to be primarily produce by activated CD4+ 
memory T cells (49), however, subsequent studies showed that CD8+ memory T cells 
can also produce IL-17A upon activation (54). More recently, pioneering studies have 
revealed a new subset of CD4+ T cells as IL-17 producers and referred as T helper 17 
(Th17). 55, 56). Naïve CD4+ T cells differentiate into Th17 cells under optimum 
antigenic stimulation in the presence of TGF-β and IL-6. This drives the subsequent 
activation of signal transducer and activator of transcription 3 (STAT3) followed by 
expression of retinoic acid related orphan receptor γt (RORγt)  (57-60).  
Th17 cells play a critical role in defense against fungi and extracellular bacteria 
(60).  Additional studies implicated the crucial role of Th17 cells in chronic inflammatory 
as well as autoimmune pathologies (60). However, slower development of adaptive Th17 
responses indicated the possibility of an innate source of IL-17, which contributed to the 
early defense mechanism against certain microorganisms (61-63). In addition to Th17 
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cells, IL-17A is also produced by γδ T cells, NK cells, NKT cells, alveolar macrophages 
as well as neutrophils (63). These studies collectively indicate an important role of IL-17 
in innate as well as adaptive immune responses. 
Although, Th1 cells constitute a significant proportion of cells during the 
development of SK lesions, the actual tissue damage appears to be the consequence of 
inflammatory events that derive primarily from neutrophils. The later cell represents the 
major cellular component of lesions at all phases of SK pathogenesis (18). The 
prominence of neutrophils in SK lesions as well as the role of IL-17A in neutrophil 
migration could indicate that the recently identified proinflammatory cytokine IL-17A 
may participate in the pathogenesis of lesion development. The role of IFN-γ producing 
Th1 cells is well studied in HSV induced corneal immunopathology, but the role of IL-17 
and Th17 cells is poorly understood. In human SK, the presence of IL-17 has been 
reported (64). Additionally, the Lausch group showed that the severity of early SK 
lesions was diminished in mice unable to respond to IL-17 because they lacked the IL-17 
receptor (65). However, the cellular source of IL-17 as well as the role this cytokine plays 
compared to other inflammatory mediators remains to be further defined. Since, Th17 
cells have less stringent requirements for antigenic stimulation (66), it is possible that 
Th17 cells may play an important role in SK pathogenesis during later stages when viral 
antigen availability is limited. Thus, it could be possible that during the acute phase of 
SK pathogenesis HSV specific Th1 cells might dominate while HSV non-specific Th17 
cells may maintain the later chronic phase. This was a driving issue that was evaluated in 
our studies with the results described in chapter II.  
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HSV Induced Corneal Angiogenesis 
 
 Another important feature of SK pathogenesis is the development of new blood 
vessels or angiogenesis in the normally avascular cornea, which together with increased 
corneal opacity due to infiltration of inflammatory cells impairs normal vision and may 
lead to blindness (4, 12, 18, 24, 33). Angiogenesis is the formation of new blood vessels 
from pre-existing blood vessels through an angiogenic remodeling and sprouting of pre-
existing angiogenic structures. Development of vasculature (Vasculogenesis) ceases after 
complete maturation of the blood vessels and most of the blood vessels remain in 
quiescent stages. However, the body needs to respond to various physiological stimuli 
and active angiogenesis can be noted in cycling ovary as well as placental development 
during pregnancy (67). In addition, various pathological conditions leading to hypoxia 
such as ischemia, tissue injury or inflammation necessitates the supply of oxygenated 
blood to the damaged tissue (67, 68). Although, blood vessels in adults are maintained in 
a quiescent state, various stimuli such as malignancy, tissue injury, ischemia, 
inflammation etc can break this quiescence leading to angiogenic sprouting from existing 
vessels. This form of angiogenesis is often referred to as pathological angiogenesis and 
plays an important role in pathogenesis of various diseases such as cancer, corneal and 
retinal disorders (4, 67, 68).   
Pathological angiogenesis when compared to physiological angiogenesis, is less 
complex and may involve the action of a single growth factor, VEGF-A and its receptors 
(68). Additionally, it is not a tightly controlled process and unbalanced growth of vessels 
often results in extensive proliferation, irregular branching with the lack of a proper and 
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functional hierarchical pattern as observed during normal angiogenesis (68). 
Furthermore, due to lack of appropriate remodeling and maturation, these newly formed 
vessels are often tortuous, abnormally developed with a large diameter, and leaky. This 
leads to severe edema in affected tissue. Moreover, a recent study revealed a differential 
gene expression pattern in endothelial cells during physiological and pathological 
angiogenesis, indicating the differential regulation of these processes (67-71). Apparently 
the neovascularization process looks simpler, but involves various molecular events 
similar to those of physiological angiogenesis. The various processes such as angiogenic 
sprouting from capillary endothelial cells, their proliferation, migration to the desired 
region, organization into tubular structures along with acquisition of pericytes and 
smooth muscle cells are essential for the proper development of functional vessels (67, 
68, 70, 71). In addition, degradation of the complex extracellular matrix is also essential 
for the development of luminal structures in solid tissue. All these events are orchestrated 
and coordinated by VEGF-A, different growth factors, matrix-metalloproteinases 
(MMPs) with spatial and temporal cues from inflammatory cells.  These cells serve as 
additional sources of VEGF-A, MMPs, different cytokines and growth factors (67, 68, 
70, 71). The role of VEGF-A in pathological angiogenesis as well as structural details of 
various types of blood vessels after ectopic VEGF-A expression are well summarized in 
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Corneal Neovascularization: An Essential Step in SK pathogenesis 
 
Corneal transparency is an essential requisite for optimal vision (72, 73) . The 
avascularity of cornea is achieved through a fine balance between pro and anti-
angiogenic factors (72, 73). Events that cause angiogenesis are disruptive to vision such 
as occurs after HSV infection of the cornea (4, 12, 24). In mice, HSV infection of the 
cornea results in sprouting of new blood vessels from limbal vessels as early as day 1 pi 
and reaches the central cornea by day 20 pi (12, 24). The newly formed vascular bed is 
often leaky and abnormal releasing inflammatory cells and cytokines into the corneal 
stroma giving rise to corneal opacity and haze and subsequent vision impairment (4, 12, 
24, 37). Although numerous studies in the past have shed light on several events 
responsible for corneal angiogenesis post HSV infection, the exact molecular 
mechanisms for this outcome are still poorly understood (4, 12, 24, 33, 37). Interestingly, 
HSV replication in corneal epithelium results in angiogenesis in the underlying stroma 
(4). Additionally, HSV does not encode any proteins, that is directly angiogenic as does 
occurs with some other viruses such as human herpes virus 8 and Orf virus (4, 74-77). 
Therefore, the mechanisms by which HSV infection drives corneal angiogenesis could 
involve a cascade of indirect events driven by different pro-angiogenic cytokines and 
factors (4). Numerous studies from our lab as well as other’s have indicated the several 
angiogenic factors can be involved. These include VEGF-A, basic Fibroblast growth 
factor (bFGF), bioactive CpG motifs, pro-inflammatory cytokines (IL-6, IL-1β) as well 
as E-L-R motif containing chemokines in HSV induced corneal neovascularization (12, 
23, 37). Although all these molecules may participate in pathological neovascularization, 
	   12	  
the VEGF family of proteins, especially VEGF-A signaling through the VEGFR-2 
receptor, is likely to be the most consequential (12, 78). In support of this, inhibiting 
VEGF or interfering with its receptor function, have been shown to be effective 
therapeutic strategies in mice models of SK (4, 12, 24, 78). 
 
Source of VEGF-A During HSV Induced Ocular Neovascularization 
 
 After ocular HSV infection of mice, VEGF-A mRNA transcripts are detectable by 
12 h pi and VEGF-A protein by 24 h pi (4, 12). However, one unresolved issue with 
regard to VEGF and pathological angiogenesis in SK, is the source of the VEGF A that 
induces the neovascularization as a consequence of the infection. Earlier studies from our 
lab demonstrated that the primary source of VEGF-A was corneal uninfected epithelial 
cells exposed to stimulating products such as IL-6 and CpG nucleotides released from 
infected and dying cells (4, 12). However, more recently, it was observed that VEGF-A 
can be produced directly by corneal epithelial cells in response to HSV infection (79). 
Additionally, infiltrating inflammatory cells, especially neutrophils, could also contribute 
to the source of VEGF-A (4, 18, 22). Interestingly, it was observed that VEGF-A is 
continuously produced in biologically functional amounts by normal uninfected corneal 
epithelial cells (73). However, this source of VEGF-A fails to induce abnormal 
angiogenesis because it is bound to a soluble form of the VEGF receptor 1 (sVEGFR-1) 
(73). This inhibitory interaction between VEGF-A and sVEGFR-1 was suggested to 
explain corneal avascularity, which is an essential feature of uninterrupted vision (72, 
73). Furthermore, an angiogenic response was observed in the normal eyes when the 
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bond between VEGF-A and sVEGFR-1 was disrupted using anti-sVEGFR-1 mAb (73).  
Also, some species fail to express sVEGFR-1 and in one genetic disease of humans, 
synthesis of the sVEGFR-1 molecule is defective (80). In light of the existence of the 
VEGF-A trap in normal eyes it could be that pathological angiogenesis, as for example 
can occur after HSV infection, could also be influenced by the balance between VEGF-A 
and the sVEGFR-1 molecules. We analyzed this possibility as one of the possible 
mechanism employed by HSV infection for corneal angiogenesis. Our results indicated 
that HSV infection of the cornea leads to an imbalance between VEGF-A and sVEGFR-1 
in favor of increased free VEGF-A thus leading to the development of angiogenesis 
(Discussed in Part III). 
 
Role of other pro-angiogenic factors in HSV induced corneal neovascularization 
 
a. CpG Motifs 
 
 In addition to the direct production of VEGF-A by HSV infected or uninfected 
corneal epithelial cells, other factors such as CpG motifs derived from viral DNA can 
stimulate paracrine production of VEGF-A by corneal epithelial and stromal cells (4, 33). 
However, it is poorly understood how CpG motifs stimulate VEGF-A production. It is 
possible that HSV DNA, a rich source of bioactive CpG motifs, can stimulate VEGF-A 
production through TLR-9 mediated signaling that leads to induction of MyD88 adaptor 
protein and subsequent induction of NFκB pathways (4, 33). Additionally, CpG repeats 
induced by HSV infection could stimulate VEGF-A induction through increased 
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production of IL-1 and IL-6, which promote paracrine expression of VEGF-A by corneal 
epithelial cells (4).  
 
b. Matrix Metalloproteinases (MMPs) 
 
Different MMPs play an important role in the breakdown of solid extracellular 
matrix and facilitates migration of endothelial cells, an essential step for the development 
of new blood vessel in solid tissue (4, 72, 81). MMPs are zinc-containing proteinases, 
secreted as pro-peptides that are activated in the extracellular milieu. They contribute to 
extracellular matrix remodeling (81). Several MMPs are expressed and localized to the 
different sites in the cornea, and they have been shown to play a role in 
neovascularization (72, 81). MMP-2, -7, -9, -14 were considered to be pro-angiogenic in 
corneal neovascularization and wound healing (72, 81). Among different MMPs, MMP-9 
was shown to play an important role in HSV induced corneal angiogenesis (23). Innate 
cells, particularly neutrophils were shown to contribute to the early source of MMP-9, 
since depletion of neutrophils with specific mAb after HSV infection resulted in reduced 
levels of MMP-9 compared to isotype control antibody treated mice (23). Although, 
inhibition of MMP-9 activity using siRNA resulted in diminished angiogenesis severity 
in HSV infected mice, the exact molecular mechanism underlying the MMP-9 mediated 
neovascularization is poorly understood (4).  
 
c. E-L-R motif containing chemokines 
 
 It has been documented that chemokines with E-L-R (tri-peptide sequence 
Glutamate-Leucine-Arignine) motifs possess angiogenic activity (4, 82, 83). HSV 
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infection of epithelial cells has been shown to up-regulate the expression of one such 
chemokine, MIP-2 (36, 84, 85). MIP-2 induced during HSV infection promotes the 
neutrophil migration at the site of inflammation thus contributing indirectly to the source 
of VEGF-A (36). Neutrophils, further contribute to the angiogenic response as they act as 
a source of preformed VEGF-A (22) as well as MMP-9 (23). Thus various chemokines 
promoting the migration of neutrophils could contribute indirectly the source of pro-
angiogenic factors and subsequent angiogenesis after corneal HSV infection. 
 
d. Pro-inflammatory cytokines: IL-1β, IL-6 and IL-17 
 
 It is known that productive HSV infection of corneal epithelial cells shuts host 
protein synthesis (86), but evidence suggests that some pro-inflammatory cytokine genes 
such as IL-1β and IL-6 are upregulated by HSV infected cells (27-29). After HSV 
infection of mouse corneal epithelial cells, both IL-1β and IL-6 expression is increased at 
day 1 pi followed by peak expression at day 10 pi (4, 27-29). Both IL-1β and IL-6 can be 
potent inducers of VEGF-A expression (87-90). Furthermore, studies from our lab have 
confirmed the role of IL-1β and IL-6 in the induction of VEGF-A by corneal epithelial as 
well as stromal fibroblast cells (4, 36, 91). In addition, intrastromal injection of IL-1β and 
IL-6 results in corneal angiogenesis in a VEGF-A dependent manner indicating their 
critical role in the induction of VEGF-A (4, 36, 91). Accordingly, blocking of IL-1β with 
the IL-1 receptor antagonist or neutralization of IL-6 with specific anti-IL-6 mAb showed 
diminished corneal angiogenic responses as compared to control treated mice post HSV 
infection (36, 37, 91).    
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 In addition to IL-1β and IL-6, IL-17 has been shown to exhibit pro-angiogenic 
activity in different angiogenesis models (48, 49, 52). IL-17A signaling through the IL-17 
receptor A induces the expression of a wide range of molecules such as VEGF-A, nitric 
oxide, prostaglandins, colony stimulating factor (CSF) - 2, CSF-3, MIP-2, CXCL1 (KC), 
CXCL2, CXCL-5, CXCL6, ICAM-1 and CCL2 by stromal fibroblast cells (48, 49, 52). 
Additionally, IL-17 also increases the expression of IL-1β, IL-6 and TNF-α by fibroblasts 
as well as monocytes (92, 93). Moreover, IL-17 was shown to play a direct role in 
angiogenesis through increased migration and cord formation of vascular endothelial 
cells in vitro as well as to increase the in vivo angiogenic response in a rat cornea assay 
(94). Since, IL-17A expression is upregulated after HSV-1 infection (64, 65), it is 
possible that IL-17A may contribute to HSV induced corneal angiogenesis. We analyzed 
this possibility for the role of IL-17A in corneal angiogenesis post HSV infection and 
results are described in chapter IV show that IL-17A promotes and orchestrates several 




 In summary, HSV infection of the cornea leads to the development of a complex 
immunopathological reaction in cornea, termed as stromal keratitis. Clinically, SK 
lesions are characterized by severe keratitis, necrosis, corneal opacity, as well as 
development of new blood vessels in the normally avascular cornea. Pathogenesis of SK 
involves several events such as viral replication, migration of cells of innate and adaptive 
immune responses, increased expression of various cytokines and chemokines as well as 
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angiogenic factors. Although, numerous past studies have elucidated the various 
molecular events responsible for the development of complex immuno-inflammatory 
lesions, mechanisms responsible for corneal angiogenesis, as well as the relative 
involvement of different subsets of CD4+ T Cells in SK pathogenesis are poorly 
understood.  
The work described in this dissertation evaluated three important aspects of HSV 
immunopathology that includes: 
1) Relative role of IL-17/IFN-γ and Th1/Th17 cells in HSV induced corneal 
immunopathology. In this study we showed that SK immunopathology was the 
outcome of a combined and sequential role of both Th1 and Th17 cells. Th1 cells 
were HSV specific migrated initially during the early stages of clinical SK 
followed by the migration of Th17 cells mostly of which were HSV non-specific. 
IL-17A contributed to the SK immunopathology by promoting HSV induced 
angiogenesis as well as increased infiltration of neutrophils. In contrast IFN-γ was 
found protective during early the stages of SK pathogenesis, but was pathogenic 
during the later stages when SK lesions were fully evident. 
2) Understanding the molecular mechanisms responsible for an imbalance between 
VEGF-A and sVEGFR-1 and subsequent corneal angiogenesis post HSV 
infection. We found that HSV infection of the cornea lead to an increased 
expression of VEGF-A, but reduced sVEGFR-1 expression. In addition to 
decreased expression of sVEGFR-1, we observed the degradation of sVEGFR-1, 
which was primarily catalyzed by MMP-2, -7 and -9. Finally, we confirmed that 
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neutrophils act as a source of additional VEGF-A as well as various sVEGFR-1 
degrading MMPs. 
 
3) Role of IL-17A mediated effects on the balance between VEGF-A and sVEGFR-
1 in HSV induced corneal neovascularization. In this study, we showed that IL-
17A expression was increased after HSV infection. IL-17A through multiple 
mechanisms contributed to the disruption of the inhibitory interaction between 
VEGF-A and sVEGFR-1. IL-17A also promoted the expression of VEGF-A, 
sVEGFR-1 degrading MMPs and CXCL1/KC a chemoattractant for neutrophils. 
The net effect was increased VEGF-A levels along with a decrease of sVEGFR-1 
with the outcome of corneal angiogenesis post HSV infection.  
 
Collectively, data presented here have identified important aspects of HSV induced 
corneal immunopathology, which can be exploited for better therapeutic management of 
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FIGURE 1.1 PRINCIPAL EVENTS IN HSV INDUCED CORNEAL SK PATHOGENESIS 
Post HSV infection of the cornea, replicating virus is detectable in the cornea till day 7 pi. 
Early after HSV infection, PMN, particularly neutrophils infiltrate the stromal layer of 
cornea, and play an important role in virus clearance. Development of new blood vessels 
from existing limbal vessels can be noted as early as day 1 pi. During clinical phase SK 
lesions become evident which are characterized by the infiltration of lymphocyte, 
particularly Th1 cells, neutrophils and the development of blood vessels. 
 
 








                                                                                                    
 
                                                             
FIGURE 1.2 CLINICAL PHASE OF SK 
Clinical phase of SK is marked by corneal infiltration of the T lymphocytes, particularly 
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Research described in this chapter is a slightly modified version of an article that is 
accepted for publication in Journal of Immunology by Amol Suryawanshi, Sachin Mulik, 
Shalini Sharma, Pradeep BJ Reddy, Sharvan Sehrawat and Barry T Rouse. 
 
Suryawanshi A, Veiga-Parga, Rajasagi N, Reddy PB, Sehrawat S and Rouse BT. Role of 
IL-17 and Th17 Cells in HSV Induced Corneal Immunopathology. J. Immunol. 2011. 187 
(4). Copyright © 2011 by The American Association of Immunologists, Inc. 
 
In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper 
includes (1) Selection of the topic (2) Compiling and interpretation of the literature (3) 
Designing experiments (4) Understanding the literature and interpretation of the results 
(5) Providing comprehensible structure to the paper (6) Preparation of graphs and figures 




Herpes Simplex Virus-1 (HSV) infection of the cornea leads to a blinding 
immuno-inflammatory lesion of the eye termed stromal keratitis (SK). Recently, IL-17 
producing CD4+ T cells (Th17) were shown to play a prominent role in many 
autoimmune conditions, but the role of IL-17 and/or of Th17 cells in virus 
immunopathology is unclear. Here we show that, after HSV infection of the cornea, IL-
17 is upregulated in a biphasic manner with an initial peak production around day 2 pi 
and a second wave starting from day 7 pi with a steady increase until day 21 pi, a time 
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point when clinical lesions are fully evident. Further studies demonstrated that innate 
cells particularly, γδ T cells, were major producers of IL-17 early after HSV infection. 
However, during the clinical phase of SK, the predominant source of IL-17 was Th17 
cells which infiltrated the cornea only after the entry of Th1 cells. By ex-vivo stimulation, 
the half fraction of IFN-γ producing CD4+ T (Th1) cells were HSV specific, whereas 
very few Th17 cells responded to HSV stimulation.  The delayed influx of Th17 cells in 
the cornea was attributed to the local chemokine and cytokine milieu. Finally, HSV 
infection of IL-17 receptor knockout mice, as well as IL-17 neutralization in WT mice 
showed diminished SK severity. In conclusion, our results show that IL-17 and Th17 
cells contribute to the pathogenesis of SK, the most common cause of infectious 




Ocular infection with herpes simplex virus (HSV) can cause a chronic 
inflammatory reaction in the corneal stroma that may culminate in blindness (1, 2). This 
stromal keratitis (SK) lesion in humans is suspected to represent an immunopathological 
reaction, a notion well supported by studies with animal models of SK (2-5). An 
inevitable consequence of ocular HSV infection is life long latency in neuronal cells of 
the trigeminal ganglion (6). In humans, periodic reactivation from some latently infected 
cells give rise to replicating virus that acts as the most common stimulus for SK lesion 
development (2-5). A major objective of SK research is to identify the role of cellular and 
molecular events involved in tissue damage and its resolution with a view to improving 
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current means of management of this often distressing disease. Studies in the mouse 
models of SK have firmly established an essential role for T cells as the principal 
orchestrators of SK lesions (7, 8). However, the actual tissue damage appearance to be 
the consequence of inflammatory events that derive primarily from neutrophils that 
represent the major cellular component of lesions at all phases of SK pathogenesis (9, 
10). The prominence of neutrophils in SK lesions could indicate that the recently 
identified proinflammatory cytokine IL-17 is a significant participant in the pathogenesis 
of lesion development. Accordingly, IL-17 functions indirectly to cause tissue infiltration 
by neutrophils, acts as a neutrophil survival factor and also may drive the cells to produce 
and release tissue damaging molecules such as MMPs and oxyradicals (11-15).  
In human SK, the presence of IL-17 has been reported (16). Additionally, the 
Lausch group showed that the severity of early SK lesions were diminished in mice 
unable to respond to IL-17 because they lacked the IL-17 receptor (17). However, the 
cellular source of IL-17 as well as the role this cytokine plays compared to other 
inflammatory mediators remains to be further defined. This is the topic of the present 
communication.  
We show that HSV infection of the cornea leads to the biphasic upregulation of 
IL-17. Initially its source was innate cells that included γδ T cells, whereas later during the 
clinical phase Th17 cells were the predominant producer. The CD4+ T cell subset 
responsible for orchestrating SK appeared to be mainly Th1 cells at all stages of SK. On the 
other hand, very few Th17 cells infiltrated into the cornea during early stages of SK (day 8 
and 15 pi) but became more prominent during very late stage of SK (day 21 pi), when SK 
lesions were fully evident. The late entry of Th17 cells was partly explained by the delayed 
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upregulation of IL-6 and TGF-β, cytokines responsible for Th17 generation, as well as 
CCL20 expression in the cornea, a chemokine responsible for the migration of Th17 cells 
at the site of inflammation. On the basis of anti-cytokine suppression and comparison of 
lesion severity between WT and IL-17 receptor knock out (IL-17RKO) mice, our result 
show that IL-17 contributes to inflammatory events during the pathogenesis of SK. Future 
therapies targeting the IL-17 response could be useful to alleviate the SK lesion severity, an 
important cause of infectious blindness in humans. 
 
Material and Methods 
 
Mice, Virus and cell lines. IL-17RA -/- mice on C57B1/6 background were obtained 
from Amgen Inc. (Thousand Oaks, CA, USA). C57BL/6 mice were purchased from 
Harlan Sprague Dawley, Indianapolis, IN. Animals were housed in the animal facilities 
approved by the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) at The University of Tennessee and all experimental procedures were in 
complete agreement with the Association for research in Vision and Ophthalmology 
resolution on the use of animals in research. HSV-1 RE Tumpey and HSV-KOS viruses 
were grown in Vero Cell monolayers (ATCC no. CCL81, American Type Culture 
Collection). The virus was concentrated, titrated, and stored in aliquots at -800 C until 
use.  
Corneal HSV Infection and Clinical Scoring. Corneal infections of mice were 
conducted under deep anaesthesia induced by i.p. injection of avertin as previously 
described (18). Mice were scarified on their corneas with 27-gauge needle, and a 3-µl 
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drop containing 1×104 PFU of virus was applied to the eye. The eyes were examined on 
different days pi for the development and progression of clinical lesion by slit-lamp 
biomicroscope (Kowa Company, Nagoya, Japan). The progression of SK lesion severity 
and angiogenesis of individually scored mice was recorded. The scoring system was as 
follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or 
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer; 
+5, corneal rupture and necrotizing keratitis. The severity of angiogenesis was recorded 
as described previously (19). According to this system, a grade of 4 for a given quadrant 
of the circle represents a centripetal growth of 1.5 mm towards the corneal center. The 
score of the four quadrants of the eye were then summed to derive the neo vessel index 
(range 0-16) for each eye at a given time point. 
Reagents and Antibodies. CD4-allophycocyanin (RM4-5), IL-17-PE (TC11-18H10), 
IFN- γ-FITC (XMG1.2), γδ TCR-FITC (GL3), anti-CD3 (145.2C11), anti-CD28 (37.51), 
purified anti-IL-17, purified anti-IFN- γ and GolgiStop (Brefeldin A) were purchased 
from BD Bioscience. Foxp3-PE, IL-17 and IFN- γ ELISA kit were purchased from 
eBioscience. Anti γδ TCR (UC3-10A6) and Hamster IgG isotype control Ab were 
purchased from Bio-X-Cell. PMA and ionomycin were purchased from Sigma-Aldrich.  
γδ T cell Depletion. C57BL/6 mice were injected on day 2 before infection with 500 
µg/mouse anti-mouse γδ TCR (clone UC3-10A6) followed by 250 µg/mouse on day of 
infection. 
Sub‐conjunctival Injection. Subconjunctival injections of anti-IL-17 were performed as 
described previously (20). Briefly, subconjunctival injections were done using a 2 cm, 
32 gauge needle and syringe (Hamilton, Reno, NV) to penetrate the perivascular region 
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of conjunctiva, and the required dose of anti-IL-17 mAb  was delivered into 
subconjunctival space. Control mice received isotype mAb. 
IL-17 and IFN-γ Neutralization. C57BL/6 mice were ocularly infected and 0.05 mg of 
anti-IL-17 or anti-IFN- γ was given intraperitoneally (i.p.) starting from day -1 followed 
by day 2 and day 5 pi  or starting from day 7 followed by day 10 and 13 pi. For local 
depletion, 5 µg anti-IL-17 mAb was administered by sub-conjunctival injection following 
same regimes as described above.  
Isolation of corneal-infiltrating cells and flow cytometry. HSV infected corneas were 
harvested from different group of mice at indicated time point pi. Six to eighth corneas 
per group were excised, pooled group wise, and digested with 60 U/ml Liberase for 35 
minutes at 370C in a humified atmosphere of 5% CO2. After incubation, the corneas were 
disrupted by grinding with a syringe plunger on a cell strainer and single-cell suspensions 
were made in complete RPMI 1640 medium. The single cell suspensions obtained from 
corneas, DLNs and spleen were stained for different cell surface molecules for FACS. All 
steps performed at 40C. Briefly, cell suspension were first blocked with an unconjugated 
anti-CD32/CD16 mAb for 30 min in FACS buffer. After washing with FACS buffer, 
samples were incubated with CD4-APC (RM4-5) for 30 min on ice. Finally, the cells 
were washed three times and re-suspended in 1% para-formaldehyde.  
To measure the number of IFN-γ, IL-17 and IL-2 producing CD4+ T cells, 
intracellular cytokine staining was performed. Briefly, 106 freshly isolated cells from 
DLNs, spleens or corneas were left untreated or stimulated with PMA plus ionomycin 
along with GolgiStop for 4 hrs at 370C in 5% CO2. To quantify IL-2 producing CD4+ T 
cells, cells were stimulated with anti-CD3 (1ug/ml) and anti-CD28 (0.5 ug/ml) for 5 hrs 
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in the presence of GolgiStop at 370C in 5% CO2. To enumerate the HSV-specific Th1 and 
Th17 cells, cells were stimulated with 2 multiplicity of UV-inactivated HSV and 
incubated overnight at 370C in 5% CO2.  GolgiStop (10mg/ml) was added for the last 5 
hrs of the stimulation. At the end of stimulation period, cell surface staining was 
performed as described above, followed by intracellular cytokine staining using 
Cytofix/Cytoperm kit (BD Pharmingen) in accordance with the manufacturer’s 
recommendations. FITC labeled IFN-γ and PE labeled IL-17 antibodies were used. After 
final washing cells were resuspended in 1% para-formaldehyde. The stained samples 
were acquired with a FACS Calibur (BD Biosciences) and the data were analyzed using 
the FlowJo software. 
Quantitative  PCR (QPCR). Corneal cells were lysed and total mRNA was extracted 
using TRIzol LS reagent (Invitrogen). Total cDNA was made with 500 ng of RNA using 
oligo(dT) primer. Quantitative PCR was performed using SYBR Green PCR Master Mix 
(Applied Biosystem, Foster City, CA) with iQ5 real-time PCR detection ssystme (Bio 
Rad, Hercules, CA). The expression levels of different molecules were normalized to β-
actin using ΔCt calculation. Relative expression between control and experimental groups 
were calculated using the 2-ΔΔCt formula. The PCR primers used were as follows  
β ACTIN- For 5’-TCCGTAAAGAATCTCATGCC-3’, Rev 5'-
ATCTTCATCCTCCTAGGAGC-3'; IFN-Υ For 5’-GGATGCATTCATGAGTATTGC-
3’, Rev 5’-GCTTCCTGAGGCTGGATTC-3’; IL17A For 5’- 
GCTCCAGAAGGCCCTCAG-3’, Rev 5’- CTTTCCCTCCGCATTGACA-3’; IL6- For 
5’- CGTGGAAATGAGAAAAGAGTTGTGC-3’, Rev 5’- 
ATGCTTAGGCATAACGCACTAGGT-3’ TGFβ-For 5'- 
	   44	  
TTGCTTCAGCTCCACAGAGA-3’, Rev 5’- TGGTTGTAGAGGGCAAGGAC-3’; 
CCL20 - For 5’-GCCTCTCGTACATACAGACGC-3’, Rev5’-
CCAGTTCTGCTTTGGATCAGC-3’. 
ELISA. The pooled corneal samples were homogenized using a tissue homogenizer and 
supernatant was used for analysis. The concentrations of  IL-17A and IFN-γ were 
measured by using sandwich ELISA kits (eBioscience) as per the manufacturer’s 
instructions. 
Statistics. Student’s t test was performed to determine statistical significance and data are 




IL-17 is up-regulated in the cornea of mice ocularly infected with HSV-1 
 
Total mRNA isolated from the corneas of HSV infected mice was analyzed for 
the relative fold changes in IL-17 mRNA expression by RT-PCR. As is evident in Figure 
2.1A, the expression profile revealed that IL-17 was upregulated in a biphasic manner. 
During the early phase, IL-17 expression was elevated at day 2 pi, but returned to near 
basal levels around day 5 pi. This was followed by a subsequent upregulation of IL-17 
starting from day 7 pi with a steady increase until day 21 pi (last observed time point), 
which corresponds to the chronic phase of the disease. In addition, quantification of IL-
17 by ELISA revealed a similar pattern of expression as observed with RT-PCR (Figure 
2.1B).  Early after HSV-1 infection, innate cells infiltrate the cornea, and CD4+ T cells 
start infiltrating the infected cornea around day 7p.i. (1). Recent studies have implicated 
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innate cells, particularly γδ T cells as one of the major sources of IL-17 (21-25). 
Therefore to investigate this possibility in our system, IL-17 producing γδ T cells were 
enumerated by intracellular cytokine staining (ICCS) after stimulation with 
PMA/ionomycin. Around 16% of total γδ T cells produced IL-17 (Figure 2.1C), and 
depletion of γδ T cells using a specific monoclonal antibody diminished the levels of IL-
17 as measured by ELISA (Figure 2.1D). Collectively, these data show that IL-17 
expression is upregulated in a biphasic manner following HSV infection and innate γδ T 
cells contribute to the early source of IL-17.  
 
Th1 cells predominate during early stages of SK pathogenesis followed by Th17 cells 
in later stages.  
 Past studies showed that CD4+ T cell infiltration of the corneal stroma becomes 
readily apparent by 7 day pi (1, 7, 8), but the relative composition of the CD4+ T effectors 
was not recorded. Using the intracellular cytokine staining approach with cells isolated 
from collagen digested pooled corneas, the relative frequencies of Th17 and Th1 cells 
were measured in the HSV infected corneas at day 8, 15 and 21 pi. As shown in Figure 
2.2A, stimulation of corneal cells with PMA and ionomycin revealed a large proportion 
of CD4+ T cells producing either IFN-γ or IL-17 within the corneal infiltrate. However, 
the ratio of frequencies of Th1 to Th17 were higher at all tested time point pi. 
Additionally, Th1 cells showed an initial increase at day 15 over day 8 pi followed by 
reduced frequencies at day 21 pi. In contrast to Th1 cells, Th17 cells were scarcely 
detectable on day 8 pi and this was followed by a gradual increase in their frequency with 
the progression of SK (Figure 2.2A). The total cell numbers for each population revealed 
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similar kinetics (Figure 2.2B, middle column). Furthermore, intracellular staining of 
corneal cells stimulated with UV inactivated viral antigen preparation revealed a high 
percentage (≤ 24.4 %) HSV specific Th1 cells as compared to a lower percentage (≤ 0.35 
%) of HSV specific Th17 cells (Figure 2.2A right column). In addition, analysis of local 
draining lymph nodes (DLN) for Th1 and Th17 cells, revealed a similar pattern as 
observed for the cornea (Figure 2.2 C, D). These results indicate Th1 cells initially 
infiltrate the site of infection followed by the increased infiltration of Th17 cells during 
late stages of SK.  
 
Local cytokine/chemokine directs delayed entry and/or differentiation of Th17 cells 
in the cornea. 
 The delayed migration of Th17 cells in the cornea could be the result of the early 
conditions suppressing Th17 cells or conditions such as local cytokine and chemokine 
milieu favoring Th17 cell generation and/or migration during later stages of SK. To 
further investigate this issue, studies were carried out for the corneal quantification of 
different cytokines as well as chemokines, particularly those that are involved in the 
generation, migration and suppression of Th17 cell responses.  Since Th17 cells 
differentiate from naïve CD4+ T cell in the presence of IL-6 and TGF-β with antigenic 
stimulation (26-28), we quantified the relative fold change of IL-6 and TGF-β at various 
days pi as compared to mock infected cornea (Figure 2.3 A and 2.3 B). The results 
showed relatively low levels of IL-6 at day 8 pi followed by a peak at day 15 pi. (Figure 
2.3A). TGF-β levels were upregulated from day 8 pi and, peaked at day 15 pi. As 
compared to day 15 pi, both IL-6 and TGF-β levels were reduced by day 21 pi. 
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Furthermore, quantification of CCL20 a known ligand for CCR6, which is preferentially, 
expressed by homeostatically proliferating Th17 cells as well as Treg cells (29, 30), was 
significantly expressed only after day 15 pi (Figure 2.3C). Furthermore, since a recent 
study has shown the suppressive role of IL-2 in the generation of Th17 cells (31), we 
quantified CD4 T cells producing IL-2 in the local DLN and spleen by ICCS assay. As 
shown in Figure 2.3D-E, IL-2 producing CD4+ T cells were significantly higher in 
frequency as well as numbers at day 8 pi followed by a reduction at day 15 and day 21 pi. 
This early and robust IL-2 production by CD4+ T cells could be responsible for the 
promotion of Th1 as well as the suppression of Th17 responses in lymphoid organs early 
after HSV infection. However, during the progression of SK, increased IL-6, TGF-β as 
well as chemokine CCL20 expression in the cornea could be responsible for either 
generation or migration of Th17 cells during the later stages of SK.  
 
The Dual Role of IFN-γ in HSV induced immunopathology 
 Since, IFN- γ suppresses the induction and expansion of Th17 cells (17, 32-34), 
we investigated the role of IFN-γ in relation to IL-17 as well as Th-17 cells. Similar to 
IL-17, IFN-γ showed biphasic upregulation. However, the second peak expression was 
observed around day 7 pi followed by a steady decline with the progression of SK 
(Figure 2.4A). Measurement of IFN-γ cytokine by ELISA revealed similar kinetics of 
expression as observed with QPCR analysis (Figure 2.4B). To demonstrate the role of 
IFN-γ in SK, IFN-γ depletion was carried out from day -1 followed by depletion on day 2 
and day 5. The severity of SK lesions was scored on day 8 and day 11. As shown in 
figure 2.4C, early depletion of IFN-γ significantly increased the severity of SK on day 8. 
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However, on day 11 it reached that of isotype antibody treated control mice group. 
Furthermore, all mice from IFN- γ depleted group showed signs of severe encephalitis, 
which necessitated termination of experiments. In contrast, depletion of the second peak 
of IFN-γ during later stages of SK (on day 7, 10 and 13) showed significantly diminished 
SK lesion severity on day 11 and day 15 pi (Figure 2.4D). The analysis of various cell 
types from the corneas showed reduced frequencies of total CD4+ T cells, the Th1 subset, 
but increased percentage of the Th17 subset (Figure 2.4E-F). However, the total numbers 
of total CD4+ T cells, Th1 and Th17 cells were reduced in IFN-γ depleted mice as 
compared to isotype treated antibody treated mice.  These results demonstrate an early 
protective role of IFN-γ likely acting by controlling virus replication in cornea. However, 
IFN-γ exerts a pathologic role once virus is cleared from the cornea as occurs during the 
later stages of SK. Taken together, our data indicates that Th1 cells are the initial main 
orchestrators of SK lesions followed later on in the chronic phase by the contribution of 
both Th1 and Th17 cells. Early infiltration of Th1 cells initiates the inflammatory 
condition particularly cytokines and chemokine environment that promotes generation 
and/or migration of highly pathogenic Th17 cells. This late migration of Th17 cells 
maintains the SK pathology via their secretion of IL-17, which acts as a pro-
inflammatory cytokine through various mechanisms. 
 
IL-17 neutralization diminishes SK lesion severity. 
 To further investigate the role of IL-17 in SK pathogenesis, the effects of 
neutralizing IL-17 with monoclonal Ab was studied over a 15 day observation period. 
Intraperitoneal Treatment was began on 1 day before infection followed by injections on 
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day 2 and day 5 pi. The early neutralization of IL-17 reduced the SK lesion severity on 
day 11 pi (Fig 2.5A). To further confirm the role of IL-17 during later stages of SK, IL-
17 neutralization was started from day 7 pi when SK lesions become evident, followed by 
depletion on day 10 and 13 pi.  This therapeutic neutralization of IL-17 also reduced the 
severity of SK lesions further confirming the pathogenic role of IL-17 during the later 
stages of SK (Fig 2.5B). In addition, therapeutic local depletion of IL-17 by 
subconjunctival administration of anti-IL-17 antibody also resulted in significantly 
diminished SK lesion scores (Fig 2.5C). Examination of corneal sections by 
histopathological analysis revealed reduced inflammatory response in the IL-17 depleted 
corneas, with less fibrosis of corneal stroma, no or minimal hypertrophy of epithelial 
layers as well as diminished infiltration of leukocytes, particularly neutrophils (Fig 2.5D). 
Moreover, the frequencies as well as total numbers of CD4+ T cells, Th1 and Th17 cells 
were also reduced in the anti-IL-17 treated group (Fig 2.5E-F). The reduced numbers of 
Th1 cells could be the result of reduced infiltration of neutrophils, which may act as a 
source of CXC chemokines essential for Th1 infiltration (35). Taken together, these data 
indicated the pathogenic role of IL-17 during early as well as late phases of SK.  
 
IL-17R KO mice show reduced SK lesion severity. 
 To further confirm the role of IL-17 in SK pathogenesis, mice lacking IL-17 
receptor signaling were ocularly infected with HSV and SK lesion severity was 
monitored and compared with WT mice. The disease severity differed significantly at all 
tested time point pi between WT and IL-17R KO mice (Fig 2.6A). The onset of SK was 
delayed and SK lesions were less severe in IL-17R KO, as compared to their WT 
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counterparts. The severity of SK lesions (scores of ≥3) was reduced in mice in the IL-17R 
KO group (3 of 8 eyes at day 21) compared to WT counterparts (7 of 8 eyes at day 21) 
(Fig 2.6A right panel). Furthermore, histopathological analysis of WT corneas at day 15 
pi showed loss of the corneal epithelial layer, extensive stromal fibrosis, infiltration of 
large number of leukocytes in the stromal layers with the resultant thickening of corneal 
stroma (Fig 2.6B, upper panels). In contrast to WT corneas, section from IL-17R KO 
corneas showed no damage to the epithelial layer with minimal fibrosis as well as 
infiltration by inflammatory leukocytes at day 15 pi (Fig 2.6B lower panels). Moreover, 
immunofluorescence staining of corneal sections for CD4+ T cells at day 15 pi showed 
diminished infiltration of CD4+ T cells in IL-17R KO mice as compared to WT mice 
(Figure 2.6C). To further quantify the different cell types infiltrating the cornea, 
experiments were terminated on day 15 to study cellular parameters. As shown, the 
frequencies (Fig 2.6D-F) and absolute numbers (Fig 2.6G) of total CD4+ T cells, Th1 and 
Th17 cells were decreased in the IL-17R KO compared to WT mice.  Additionally, the 
expression of pro-inflammatory cytokines such as IL-6, IL-17, IL-1β were diminished in 
IL-17R KO mice corneas as compared to the WT samples (data not shown).  Analysis of 
DLN and spleen of WT and IL-17R KO, mice showed reduced frequencies, but not total 
cell numbers of each population (Fig 2.7). As shown in Figure 7A-D, the frequencies of 
Th1 and Th17 cells showed two fold reduction in DLNs and spleen from IL-17R KO 
mice as compared to WT mice. However, the total numbers of each subpopulation were 
equal in both IL-17R KO and WT mice DLNs and spleen (Fig 2.7E and F). These 
observations revealed that although, the total cell numbers were equal in DLNs and 
spleens from IL-17R KO and WT mice, the frequencies and total cell numbers were 
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reduced at the inflammatory site (cornea) in IL-17R KO mice as compared to WT 
counterparts. Taken together, these results indicated the pro-inflammatory role of IL-17 





 In this study we show that HSV infection of the cornea leads to a biphasic 
increase in corneal expression of IL-17. Moreover, the subsequent HSV induced SK 
immunopathology is the outcome of the effector functions mediated by both Th1 and 
Th17 cells. The pro-inflammatory cytokine IL-17 drives initial as well as late events in 
SK pathogenesis and also contributes significantly to the pathology of SK. However, the 
sources of IL-17 during early and late stages of SK were different. Initially, innate cells 
such as γδ T cells were the main producers and later on in the chronic phase Th17 cells 
were the producers. Additionally, IFN-γ was shown important for the early protection 
from HSV infection, but cells producing IFN-γ also contributes to the pathology once the 
virus is absent.  Furthermore, HSV induced immunopathological lesions involve both 
Th1 and Th17 cells with their respective importance changing with time. Accordingly, in 
line with previous published reports, our data demonstrates that Th1 cells mainly initiate 
and orchestrate SK lesions at least during the early stages followed by the entry of Th17 
cells when the disease is at peak. Interestingly, significant proportion of Th1 cells 
secreted IFN- γ upon stimulation with UV inactivated HSV virus, but most Th17 cells 
failed to produce IL-17 under similar conditions, indicating that Th17 cells could be 
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involved in a bystander fashion in SK pathogenesis. Furthermore, depletion of IL-17 
during both early as well as during the chronic phase of SK pathogenesis and infection of 
IL-17R KO mice showed reduced SK lesion severity. The findings indicate an important 
role for IL-17 at all stages of SK pathogenesis. Accordingly targeting IL-17 production 
represents a logical target to control SK, an important cause of human blindness.  
 Innate cells such as γδ T cells act as one of the major early sources of IL-17, as 
shown in some other systems (21-25). Thus our data is in line with the previously 
published reports where γδ T cells were shown to be main source of innate IL-17 (21-25). 
IL-17 orchestrates the local inflammatory response by stimulating epithelial, endothelial 
and fibroblastic cells to produce and release various inflammatory cytokines (12, 36-39).  
Furthermore, IL-17 drives increased influx, as well as survival, of neutrophils at the site 
of inflammation by the induction of neutrophil chemoattracts, as well as GM-CSF 
mediated granulopoeisis (12, 39-41). In ocular HSV infection, an initial influx of 
neutrophils plays an important role in virus clearance (42). The diminished expression of 
neutrophil chemoattractants for neutrophils and subsequent reduced infiltration of 
neutrophils occurs in IL-17R KO mice post HSV infection (17). Similarly, we found a 
reduced infiltration of neutrophils in HSV infected IL-17R KO mice as well as post IL-17 
neutralization during early as well as during late stages of SK pathogenesis (data not 
shown). Taken together, the data show that during HSV infection of the cornea, IL-17 
contributes to the early innate cell response by promoting the migration of neutrophils. 
Recent work has discovered a critical role of Th17 cells in various chronic and 
autoimmune inflammatory conditions (33, 34, 43-45), and our data show that Th17 cells 
do participate in SK pathogenesis. However, in contrast to autoimmune as well as some 
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chronic inflammatory conditions, where Th17 cells may play a dominant role, HSV 
induced immunopathology results from the participation of both Th1 and Th17 cells with 
the relative importance changing as disease progresses. Accordingly, our data from IFN-γ 
and IL-17 neutralization as well as IL-17R KO mice shows that both Th1 and Th17 
mediated immune response contributes to SK pathogenesis. Th1 cells were the first to 
infiltrate the cornea, and significant proportions of them were HSV-specific. They set the 
stage for the development of complex SK lesions that additionally involves Th7 cells. 
However, the Th17 cells could migrate only after the entry of Th1 cells, indicating their 
role in the later stages of SK. Our data accord with a recent study showing that only Th1 
cells could gain entry in the non-inflamed tissue and initiate inflammatory response 
followed by entry of Th17 cells in the inflamed CNS (46). Furthermore, almost none of 
the Th17 cells responded to HSV specific antigen when stimulated ex-vivo which may 
indicate their bystander role in SK pathogenesis. However, diminished SK severity in the 
absence of IL-17 receptor signaling, as well as post IL-17 neutralization during early as 
well as late stages of SK, indicated that IL-17 does play a pro-inflammatory role in SK 
pathogenesis.  
Although, presently we cannot detect the antigen specificity of these Th17 cells, 
they could be reactive against yet unidentified unmasked self-corneal antigens or be 
functioning in a bystander fashion. A recent study on an autoimmune condition of the 
retina using experimental autoimmune uveitis model, showed that both the retinal antigen 
specific Th1 and Th17 cells could drive autoimmunity depending upon the local 
conditions at the time of antigen exposure as well as type of T effector cell present (47). 
However, our data show that during viral immunopathology, higher levels of IFN-γ occur 
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early after HSV infection could promote Th1 and suppress Th17 immune responses. 
During autoimmune conditions exposure of self-unmasked antigens occur that provides 
constant stimulation to the T effector cells at the site of inflammation (48). The body 
might sense this chronic persistence of antigen as the need arises for stronger and more 
pathogenic immune response for the removal of such persistent antigen. The highly 
pathogenic nature of IL-17 and or Th17 cells meets this criterion and might be the 
outcome of such persistent antigenic stimulation as observed in many autoimmune 
conditions. However, during acute infections, effective Th1 and Th2 responses could 
clear the antigen from the site of infection, avoiding the Th17 mediated 
immunopathology. In contrast, chronic persistence of antigen could be sensed by the 
body, with a resultant robust T effector response such as a Th17 cell mediated immune 
response, which can cause damage and subsequent immunopathology. SK, being a 
chronic disorder could mimic this condition, where initial acute viral infection is 
controlled by the Th1 cell response that initiates inflammatory milieu in the cornea. This 
initial damage to the corneal tissue could uncover self-antigens that help drive the 
subsequent Th17 mediated highly inflammatory reaction. Alternatively, one recent study 
showed that Th17 cells can be activated in the context of the local microenvironment and 
could cause tissue specific damage in an antigen non-specific way that depended upon 
the presence of IL-6 (49).  Thus, it might be possible that these Th17 cells during late 
stages of SK could be non-specific to the corneal Ag and acting in a bystander fashion 
stimulated in the presence of the complex inflammatory cytokine milieu. However, this 
issue needs to be addressed further using adoptive transfer of non-specific Th17 cells in 
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the context of HSV induced SK immunopathology. Such studies are currently undergoing 
in our laboratory. 
Our data also demonstrates a dual role of IFN-γ during HSV mediated 
immunopathology. Innate cells contribute to the early source of IFN-γ after HSV 
infection and Th1 cells from day 7 pi (1, 50). Thus, IFN-γ neutralization during the pre-
clinical phase when replication virus is still present in cornea (1), lead to the transient 
increased tissue damage presumably driven by virus. Furthermore, this early depletion 
caused severe encephalitis, possibly an effect of higher viral titers indicating the early 
protective role of IFN-γ as previously documented (1, 49, 51). Interestingly, 
neutralization of IFN-γ after day 7 pi resulted in significantly reduced SK severity 
indicating a crucial role of IFN-γ and/or Th1 cells as the initiators and main orchestrators 
of early immunopathological lesions of SK. Since, IL-2 and IFN-γ suppresses Th17 
response (17, 31-34), conceivably during HSV induced immunopathology higher levels 
of IFN-γ in the cornea could be suppressing the early development of Th17 responses. 
Furthermore the chronic inflammatory situation in the cornea might be creating 
appropriate conditions for the generation and or migration of Th17 cells. Naïve CD4+ T 
cells differentiate into Th17 cells under appropriate antigenic stimulation in the presence 
of IL-6 and TGF-β (26-28). Furthermore, Th17 cells express the chemokine receptor, 
CCR6, and migrate to the site of inflammation through the specific chemokine, CCL20 
(29, 30). Indeed, our data for the expression levels of IL-6, TGF-β and CCL20 indicated 
that conditions favored either migration and/or generation of Th17 cells occur only 
during the very late stage of SK pathogenesis. This might explain the delayed appearance 
of Th17 cells in the cornea.  
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Taken together, our results demonstrate the relative contribution of IL-17/Th17 and  IFN-
γ/Th1 cells in the pathogenesis of SK. Both cell types participate in the pathogenesis of 
SK depending on the stage of SK. The demonstration of the pathogenic role of IL-
17/Th17 cells in later stages of SK is a novel finding and could have implication for 
future therapeutic intervention for HSV induced immunopathology, an important cause of 
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FIGURE 2.1. IL-17 EXPRESSION IS UPREGULATED IN THE HSV INFECTED CORNEA AND 
INNATE CELLS CONTRIBUTE TO THE EARLY SOURCE OF IL-17.  
C57BL/6 mice were ocularly infected with 1X 10 4 PFU of HSV. Control mice were 
mock infected with PBS. At each time point 6 corneas were collected and pooled for 
measurement of IL-17 levels by RT-PCR, ELISA or ICCS assay. (A-B) The kinetic 
analysis for the expression of IL-17 in the HSV infected cornea as determined by RT-
PCR (A) and ELISA (B). The expression levels of IL-17 by RT-PCR at various time 
points were quantified relative to β-actin using ΔΔCT method. (C) On day 2 pi, corneas 
were collected and analyzed by ICCS assay for the production of IL-17 by γδ T cells. 
Cells were stimulated with PMA/Ionomycin for 4 hrs in the presence of Brefeldin A. (D) 
The IL-17 levels at day 2 pi in γδ T cell depleted C57BL/6 mice as determined by 
ELISA. Animals in the control group received isotype antibody. Data are shown for one 
representative experiment out of two with 6 to 8 mice at each indicated time point pi. 
Statistical levels of significance were analyzed by Student’s t test. Error bars ar 
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FIGURE 2.2. KINETIC ANALYSIS OF TH1 AND TH17 CELLS IN THE CORNEA AND DLN OF 
HSV INFECTED MICE. 
C57BL/6 mice were ocularly infected with 1X 10 4 PFU of HSV and each time 
point 6 to 8 corneas were collected, pooled and liberase digested. The corneal single cell 
suspensions were analyzed for the CD4+ T cell expression of IL-17 and IFN-γ by ICCS 
assay. (A) Representative FACS plots for the corneal Th1 and Th17 cells at each time 
point pi. The cells were either un-stimulated (left column) or stimulated with 
PMA/Ionomycin for 4 hrs (middle column) in the presence of Brefeldin A. For 
quantification of Ag-specific CD4+ T cells (right panel), cells were stimulated for 16 hrs 
with UV-inactivated HSV-KOS, with the addition of Brefeldin A for last 5 hrs of 
stimulation. FACS plots shown are gated on CD4+ T cells. The ratio shown on the right 
side is a comparison of PMA/Ionomycin stimulated Th1 to Th17 cells on respective day 
pi. (B) Total number Th1 and Th17 cells per cornea at day 8, 15 and 21 pi by ICCS assay 
post stimulation with PMA/Ionomycin. (C) Representative FACS plot for Th1 and Th17 
cells from the local DLN of HSV infected mice at day 8, 15 and 21 pi. The cells were 
either un-stimulated or stimulated with PMA/Ionomycin for 4 hrs or with UV-HSV-KOS 
for 16 hrs. (D) Frequencies and total numbers (E) of Th1 and Th17 cells from DLN at 
day 8, 15 and 21 pi as determined by ICCS assay post stimulation with PMA/Ionomycin. 
Data are shown for one representative experiment out of two with 6 to 8 mice at each 
indicated time point pi. Statistical levels of significance were analyzed by Student’s t test. 
Error bars are SEM.  
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FIGURE 2.3. DELAYED EXPRESSION OF IL-6, TGF-Β AND CCL20 ALONG WITH 
REDUCED IL-2 EXPRESSION BY CD4+ T CELLS DIRECTS THE DELAYED GENERATION 
AND/OR ENTRY OF TH17 CELLS. 
C57BL/6 mice were ocularly infected with 1X 10 4 PFU of HSV. Control mice were 
mock infected with PBS. Mice were sacrificed on day 8, 15 and 21 pi and corneas, local 
DLN and spleen were collected for the analysis by RT-PCR and ICCS assay. (A-C) At 
each time point 6 corneas were collected and pooled for the measurement of IL-6 (A), 
TGF-β (B) and CCL20 (C) levels by RT-PCR. The expression levels of different 
molecules were quantified relative to β-actin using ΔΔCT method. The IL-2 producing 
CD4+ T cells were analyzed by ICCS assay as described in materials and methods. 
Representative FACS plots (D) and total cell numbers (E) for IL-2 producing CD4+ T 
cells from the DLN and spleen at day 8, 15 and 21 day pi. Cells are gated on CD4+ T 
cells. Data are shown for one representative experiment out of two with 6 mice at each 
indicated time point pi. Statistical levels of significance were analyzed by Student’s t test. 
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FIGURE 2.4. EARLY PROTECTIVE AND LATE PATHOLOGIC ROLE OF IFN-Γ IN SK 
C57BL/6 mice were ocularly infected with 1X 10 4 PFU of HSV. Control mice 
were mock infected with PBS. At each time point 6 corneas were collected and pooled 
for measurement of IFN- γ levels by RT-PCR, ELISA or for analysis by ICCS assay. (A-
B) The kinetic analysis for the expression of IFN-γ in the HSV infected cornea as 
determined by RT-PCR (A) and ELISA (B). The expression levels of IFN-γ by RT-PCR 
at various time points were quantified relative to β-actin using ΔΔCT method. (C-D) 
Diminished SK lesion severity in mice treated with anti-IFN- γ as compared to isotype 
Ab treated mice. Group of 2 to 4 mice were treated i.p. with anti-IFN- γ on either starting 
from day -1, followed by treatment on day 2 and day 5 pi (C); or either starting from day 
7 pi followed by treatment on day 10 and 13 pi (D). Mice in control group received 
isotype control Ab. (E-H) Mice from experiment (D) were sacrificed on day 15 pi and 
corneas were collected for the analysis of different cell population by flow cytometry. 
Representative FACS plots for total corneal infiltrating CD4+ T cells (E) and Th1 and 
Th17 cells after stimulation with PMA/Ionomycin (F) from isotype and anti-IFN-γ 
treated groups. (G) Total cell number per cornea for CD4+ T cells, Th1 and Th17 cells 
shows reduced infiltration of cells in the cornea after IFN-γ neutralization. Data are a 
representative summary of two independent experiments. Statistical levels of significance 
were analyzed by Student’s t test. Error bars are SEM. 
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FIGURE 2.5. IL-17 NEUTRALIZATION DIMINISHES SK LESION SEVERITY. 
C57BL/6 mice ocularly infected with 1X104 PFU of HSV were divided into two groups 
each with 6 to 8 mice. One group of mice received antibody against IL-17 and mice in 
control group were administered with isotype antibody. (A-C) Diminished SK lesion 
severity in mice treated with anti-IL-17 mAb. SK lesion score for individual cornea on 
day 15 pi (right) are shown. (A) Early neutralization of IL-17 was carried by i.p. injection 
of anti-IL-17 mAb from day -1 followed by day 2 and 5 pi. (B) Late neutralization of IL-
17 was carried by i.p. injection of anti-IL-17 mAb from day 7 followed by day 10 and 13 
pi. (C) Local depletion of IL-17 was carried by sub-conjunctival delivery of anti-IL-17 
using same strategy as that of late depletion. (D) Representative H&E stained corneal 
sections of isotype treated (top panel) and IL-17 depleted (bottom panel) mice collected 
on day 15 pi from experiment B. The figure shows the pictures of the section taken at X 
10 (left), X 20 (middle) and X 100 (right) of original magnification. (E-F) Mice from late 
depleted groups (as shown in B) were sacrificed on day 15 pi and corneas were harvested 
and pooled group wise for the analysis of various cell types (n = 6-8 per group) by flow 
cytometry. Representative FACS plot for total corneal infiltrating Th1 and Th17 cells (E) 
from isotype and anti-IL-17 treated groups. (F) Total cell number per cornea for CD 4+ T 
cells, Th1, Th17 cells shows reduced infiltration of cells in the cornea after IL-17 
neutralization. Data are a representative summary of two independent experiments. 
Statistical levels of significance were analyzed by Student’s t test. Error bars are SEM. 
Statistical levels of significance were analyzed by Student’s t test. Error bars are SEM. 
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FIGURE 2.6. IL-17R KO MICE ARE RESISTANT TO SK.  
 C57BL/6 and IL-17R KO mice were infected with 1X104 PFU of HSV. (A) The 
disease progression kinetics and SK severity was assessed on day 8, 11, 15 and 21 pi (left 
panel). Right panel shows the score of individual eye on day 15 pi (B) Representative 
H&E stained corneal sections from WT (upper row) and IL-17R KO (lower row) mice 
collected on day 15 pi. The figure shows the pictures of the section taken at X 10 (left), X 
20 (middle) and X 100 (right) original magnification. (C) Representative 
immunofluorescence micrograph of corneas for CD4+ T cells (green) from WT and IL-
17R KO mice on day 15 pi. The sections were counterstained with propidium iodide 
(red). Scale bars, 75µm. Mice were sacrificed on day 15 pi and corneas were harvested 
and pooled group wise for the analysis of various cell types (n = 6-8 per group). (D) 
Representative FACS plots for corneal infiltrating total CD4+ T cells.  (E) Intracellular 
staining was conducted to quantify Th1 and Th17 cells by stimulating them with 
PMA/Ionomycin (top) and HSV-KOS virus (bottom). (F) The bar diagram shows the 
average frequencies of Th1 and Th17 cells after stimulation with PMA/ionomycin or UV 
inactivated HSV-KOS from two independent experiments. (G) The bar diagram is a 
summary for total numbers of corneal infiltrating CD4+ T cells, IFN-γ+ CD4+ T cells, 
HSV stimulated IFN- γ+ CD4+ T cells, IL-17+ CD4+ T cells, HSV-Stimulated IL-17+ 
CD4+ T cells in the corneas of WT and IL-17R KO mice. Data are shown as a summary 
of two independent experiments with 6 to 8 mice per group.  Statistical levels of 
significance were analyzed by Student’s t test. *< 0.05; ***< 0.001. Error bars are SEM. 
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FIGURE 2.7. IL-17R KO MICE EXHIBIT REDUCED FREQUENCIES BUT NOT NUMBERS OF 
TH1 AND TH17 CELLS IN DLN AND SPLEEN POST HSV INFECTION.  
C57BL/6 and IL-17R KO mice were infected with 1X104 PFU of HSV. Mice 
were sacrificed on day 15 pi and single cell suspensions of the individual spleen and 
draining cervical lymph nodes (DLN) were prepared.  (n = 4). (A) Representative FACS 
plots for Th1 and Th17 cells stimulated with PMA/Ionomycin (top) or HSV-KOS virus 
(bottom). (B, C) Summary for average frequencies of different CD4+ T cell types as 
depicted in A from DLN  (B) and spleen (C). (D, E) The total numbers of IFN-γ+ CD4+ T 
cells, HSV stimulated IFN- γ+ CD4+ T cells, IL-17+ CD4+ T cells, HSV-Stimulated IL-
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PART-III 
AN IMBLANCE BETWEEN VEGF-A AND 
sVEGFR-1 MEDIATES CORNEAL 
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Research described in this chapter is a slightly modified version of an article that is 
accepted for publication in Journal of Immunology by Amol Suryawanshi, Sachin Mulik, 
Shalini Sharma, Pradeep BJ Reddy, Sharvan Sehrawat and Barry T Rouse. 
 
Suryawanshi A, Mulik S. Sharma S, Reddy PB, Sehrawat S and Rouse BT. Ocular 
neovascularization caused by herpes simplex virus type 1 infection results from 
breakdown of binding between vascular endothelial growth factor A and its soluble 
receptor.  J Immunol. 2011. 186, 3653-3665. Copyright © 2011 by The American 
Association of Immunologists, Inc. 
 
In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper 
includes (1) Selection of the topic (2) Compiling and interpretation of the literature (3) 
Designing experiments (4) Understanding the literature and interpretation of the results 
(5) Providing comprehensible structure to the paper (6) Preparation of graphs and figures 
(7) Writing and editing.  
 
Abstract 
The normal cornea is transparent which is essential for normal vision and 
although the angiogenic factor VEGF-A is present in the cornea, its angiogenic activity is 
impeded by being bound to a soluble form of the VEGF receptor-1 (sVEGFR-1 or sVR-
1). This report investigates the effect on the balance between VEGF-A and sVEGFR-1 
that occurs following ocular infection with HSV, that causes prominent 
neovascularization, an essential step in the pathogenesis of the vision-impairing lesion, 
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stromal keratitis (SK). We demonstrate that HSV-1 infection causes increased production 
of VEGF-A, but reduces sVEGFR-1 levels resulting in an imbalance of VEGF-A and 
sVEGFR-1 levels in ocular tissues. Moreover, the sVEGFR-1 protein made was degraded 
by the metalloproteinase (MMP) enzymes MMP-2, MMP-7 and MMP-9 produced by 
infiltrating inflammatory cells that were principally neutrophils. Inhibition of neutrophils, 
or inhibition of sVEGFR-1 breakdown with the MMP inhibitor (MMPi) marimostat, or 
the provision of exogenous recombinant sVEGFR-1 protein all resulted in reduced 
angiogenesis. Our results make the novel observation that ocular neovascularization 
resulting from HSV infection involves a change in the balance between VEGF-A and its 
soluble inhibitory receptor. Future therapies aimed to increase the production and activity 




Normal ocular function requires that photons can passage through ocular tissues 
anterior to the retina with minimal impedance. In consequence, tissues anterior to the 
retina are transparent and numerous strategies are used by the normal eye to maintain 
transparency. These include mechanisms to suppress inflammatory and immune reactions 
and means to suppress ocular vascularization, both enemies of normal vision (1, 2). 
Nevertheless, in some circumstances, damage to the eye can result in chronic 
inflammatory reactions and/or pathological neovascularization and these events may 
seriously impair vision. This is often the outcome of ocular infection with Herpes 
Simplex virus 1 (HSV-1) (3,4). Invariably, HSV-1 infection is followed by lifelong viral 
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persistence and this source of virus can give rise to subsequent infections in the cornea (5, 
6). Repeated recurrences often result in significant vision impairing lesions that occur 
mainly in the corneal stroma (5, 6). Such stromal keratitis (SK) lesions have a complex 
pathogenesis but result mainly from T cell orchestrated immunopathological reactions to 
viral or perhaps unmasked ocular antigens (5, 7). Characteristically, SK also includes 
pathological neovascularization that can be extensive, especially in animal models of SK 
(8). 
The therapeutic management of SK usually targets the inflammatory reaction but 
controlling pathological angiogenesis also represents a useful approach, as has been 
demonstrated in experimental situations (9, 10). Although several molecules may be 
involved in pathological neovascularization, the VEGF family of proteins, especially 
VEGF-A signaling through the VEGFR-2 receptor, is likely to be the most consequential 
(11, 12). In support of this, inhibiting VEGF-A, or interfering with its receptor function, 
were shown to be effective therapeutic strategies in mice models of SK (8-10). 
One unsolved issue with regard to VEGF-A and pathological angiogenesis in SK, is the 
source of the VEGF-A that induces neovascularization. Initial studies indicated that 
VEGF-A was synthesized de novo in epithelial cells as a consequence of the infection, 
although it is not clear if the primary source of VEGF-A is virus infected cells 
themselves or nearby cells exposed to products released from infected and dying cells 
(13, 14). Another VEGF-A source, especially after the initial event of SK pathogenesis, 
may be infiltrating inflammatory cells, especially neutrophils that are prominent cells in 
SK lesions (8). More recently, it was realized that VEGF-A is continuously produced in 
biologically functional amounts by corneal epithelial cells. However, this source of 
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VEGF-A fails to mediate angiogenesis because it is bound to a soluble form of the VEGF 
receptor 1 (sVEGFR-1-1) (15). This so-called VEGF-A trap may be the primary reason 
the undamaged cornea is not vascularized (15). Curiously, angiogenesis can be elicited in 
the normal eye if the bond between VEGF-A and sVEGFR-1-1 is disrupted in some way 
(15). Of interest, some species fail to express sVEGFR-1-1 and in one genetic disease of 
humans, synthesis of the sVEGFR-1-1 molecule is defective (16). Both situations result 
in corneal vascularization. 
In light of the existence of the VEGF-A trap in normal eyes, pathological 
angiogenesis, as for example can occur after HSV-1 infection, could also be influenced 
by the balance between VEGF-A and the sVEGFR-1-1 molecules. We analyze this 
possibility in the present communication. Our results confirm the previous report that 
VEFG-A is present and bound to sVEGFR-1-1 in normal ocular tissue (15). We further 
show that one consequence of HSV-1 infection is the occurrence of an imbalance in the 
levels of VEGF-A and sVEGFR-1-1 mRNA and proteins. Our results could mean that 
therapies designed to increase the presence, or retard the breakdown, of sVEGFR-1 may 
be useful approaches to help manage the severity of SK, an important cause of blindness.  
 
MATERIALS AND METHODS 
Mice, Virus and cell lines. Female 6 to 8 week old C57BL/6 mice were purchased from 
Harlan Sprague Dawley, Indianapolis, IN. Animals were housed in the animal facilities 
approved by the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) at The University of Tennessee and all experimental procedures were in 
complete agreement with the Association for research in Vision and Ophthalmology 
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resolution on the use of animals in research. HSV-1 RE Tumpey and HSV-KOS viruses 
were grown in Vero Cell monolayers (ATCC no. CCL81, American Type Culture 
Collection). The virus was concentrated, titrated, and stored in aliquots at -800 C until 
use. MK/T-1 cell line (Immortalised keratocytes from C57/BL6 mouse corneal stroma) 
was kindly gifted by Dr. Reza Dana, Schepens Eye Research Institute and Department of 
Ophthalmology, Harvard Medical School, Boston MA. 
Corneal HSV-1 Infection and Clinical Scoring. Corneal infections of C57BL/6 mice 
were conducted under deep anaesthesia induced by i.p. injection of avertin as previously 
described (8). Mice were scarified on their corneas with 27-gauge needle, and a 3-µl drop 
containing 1×104 PFU of virus was applied to the eye. The eyes were examined on 
different days pi for the development and progression of clinical lesion by slit-lamp 
biomicroscope (Kowa Company, Nagoya, Japan). The progression of SK lesion severity 
and angiogenesis of individually scored mice was recorded. The scoring system was as 
follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or 
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer; 
+5, corneal rupture and necrotizing keratitis. The severity of angiogenesis was recorded 
as described previously (17). According to this system, a grade of 4 for a given quadrant 
of the circle represents a centripetal growth of 1.5 cm towards the corneal center. The 
score of the four quadrants of the eye were then summed to derive the neo vessel index 
(range 0-16) for each eye at a given time point. 
Sub-conjunctival Injection. Subconjunctival injections of different drugs were 
performed as described previously (18). Briefly, subconjunctival injections were done 
using a 2-cm, 32-gauge needle and syringe (Hamilton, Reno, NV) to penetrate the 
	   87	  
perivascular region of conjunctiva, and the required dose of sVEGFR-1 or MMPi was 
delivered into subconjunctival space. Control mice received isotype fusion protein or 
solvent used for MMPi. 
Treatment of mice with rsVEGFR-1‐1 and MMP inhibitor. 6- to 8-wk-old C57/BL6 
mice were ocularly infected under deep anesthesia with 1×104 PFU of HSV-1 RE 
Tumpey and divided randomly into groups. One group of mice was administered with 5 
µg of rsVEGFR-1-1 (R & D Systems, Minneapolis, MN) in 7 µl PBS subconjunctivally 
on 36 hours p.i. and then every alternate day from day 5 until day 13 postinfection. In 
some experiments, rsVEGFR-1-1 was injected subconjunctivally every alternate day 
starting from day 7 until day 13 postinfection. Animals in the control group were given 
recombinant human IgG1 Fc protein (R & D Systems) following either of the regimens 
for respective experiment. The MMPi, marimastat (200 µg /mouse) (Tocris Cookson Inc, 
Ellisville, MO) was administered subconjunctivally either starting from day 2 or day 5 pi 
followed by every alternate day until day 13pi. Mice in the control group were given the 
mock injections. Mice were observed for the development and progression of 
angiogenesis and SK lesions severity from day 7 until day 15 pi. In some experiments 
MMPi treatment was started from day 2 and continued every alternate day until day 6 pi. 
Mice were sacrificed on day 7 pi and corneas were collected for further analysis. All the 
experiments were repeated at least two times. 
Neutrophil Depletion with mAb. 6 to 8 week old C57/BL6 mice were ocularly infected 
under deep anesthesia with 1×104 PFU of HSV-1 RE Tumpey and divided randomly into 
groups. One group of animals was administered with 100 µg of anti-Gr-1 mAb (RB6-
8C5; BioXcell, West Lebanon, NH) intraperitoneally on day 7 and 9 pi. Experiments 
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were terminated on day 11 pi and corneal samples were collected for further analysis. To 
study the effect of neutrophil depletion on HSV-1 mediated corneal angiogenesis, 
antibody treatment was given every alternate day starting from day 7 until day 13 pi. 
Mice were observed for the development and progression of angiogenesis and SK lesions 
until day 15 pi. Animals in control group were given isotype control (IgG2b) Ab (LTF-2; 
BioXcell) following the same regimen. All experiments were repeated at least two times. 
Immunofluorescence staining. For immunofluorescence staining, the eyes from naïve 
uninfected mice were enucleated, and snap frozen in OCT compound. Six-micron thick 
sections were cut, air dried, and fixed in acetone-methanol (1:1) at room -20 0C for 10 
min. Sections were blocked with 10% goat serum containing 0.05% Tween20 and 1:200 
dilution of Fc block (Clone 2.42G2; BD Biosciences Pharmingen, San Diego, CA). Rat 
anti-sVEGFR-1-1 (141515; R & D Systems) was diluted in 1% BSA containing 0.1% 
Triton-X and incubated at room temp for 1 hr. After incubations sections were washed 
several times with PBST and then stained with rabbit anti rat Alexa-488 for 45 min. The 
corneal sections were repeatedly washed with PBST and mounted with ProLong gold 
antifade mounting media containing DAPI as a nuclear stain (Molecular Probes, 
Invitrogen) and visualized under a Immunofluorescence microscope. For Whole mount 
corneal staining, corneas from rsVEGFR-1-1 and Isotype treated mice were dissected 
under stereomicroscope. Corneal whole mounts were rinsed in PB for 30 min and 
flattened on a glass slide under stereomicroscope. Corneal flat mounts were dried and 
fixed in 100% acetone for 10 min at - 200C. Nonspecific binding was blocked with 5% 
BSA containing 1:200 dilution of Fc block for 2 hr at 370C. CD31-PE (MEC13.3; BD 
Biosciences-Pharmingen) antibody was used t a concentration of 1:250 in 1% BSA for 
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overnight followed by subsequent washes in PBS. Corneas were mounted with ProLong 
Gold antifade and visualized with fluorescence microscope. 
Purification of Neutrophils. Ly6G+ neutrophils were purified from the pooled liberase 
(Roche Diagnostics, Indianapolis, IN) digested corneal single cell suspension obtained 
from HSV infected mice using anti-Ly6G+ microbeads (Miltenyi Biotec, Auburn, CA). 
The purity was achieved at the extent of 90%. Purified neutrophils were further analyzed 
by reverse transcription-PCR and WB for the expression of different MMPs. 
Flow Cytometry. Corneas were excised, pooled group wise, and digested with 60 U/ml 
Liberase for 35 minutes at 370C in a humified atmosphere of 5% CO2. After incubation, 
the corneas were disrupted by grinding with a syringe plunger on a cell strainer and a 
single-cell suspension was made in complete RPMI 1640 medium. The single cell 
suspensions obtained from corneas were stained for different cell surface molecules for 
FACS. All steps performed at 40C. Briefly, cell suspension was first blocked with an 
unconjugated anti-CD32/CD16 mAb for 30 min in FACS buffer. After washing with 
FACS buffer, samples were incubated with CD45-allophycocyanin (30-F11), CD11b-
PerCP (M1/79), Ly6G-PE (1A8), CD4-allophycocyanin (RM4.5) (All from BD 
Biosciences-Pharmingen) for 30 min on ice. Finally, the cells were washed three times 
and re-suspended in 1% para-formaldehyde. The stained samples were acquired with a 
FACS Calibur (BD Biosciences) and the data were analyzed using the FlowJo software. 
Quantitative  PCR (QPCR). Corneal cells were lysed and total mRNA was extracted 
using TRIzol LS reagent (Invitrogen). Total cDNA was made with 1 µg of RNA using 
oligo(dT) primer. Quantitative PCR was performed using SYBR Green PCR Master Mix 
(Applied Biosystem, Foster City, CA) with iQ5 real-time PCR detection ssystme (Bio 
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Rad, Hercules, CA). The expression levels of different molecules were normalized to β-
actin using ΔCt calculation. Relative expression between control and experimental groups 
were calculated using the 2-ΔΔCt formula. The PCR primers used are included as table 1 in 
Supplemental information. 
Reverse Transcription Polymerase chain reaction (RT‐PCR). RT-PCR was 
performed to detect the presence of mRNA transcripts of various molecules (VEGF-A, 
sVEGFR-11, beta actin and different MMPs) according to manufacturers protocol 
(Promega, Madison, WI). Briefly, cDNA was prepared from total mRNA extracted from 
different samples. cDNAs were amplified by PCR and were resolved on 1% agarose gel 
The PCR primers used are included as table 1 in Supplemental information. The PCR 
primers used are shown in table 2 in Supplemental information. 
Western blot analysis. The supernatants from lysed corneal cells were quantified using 
BCA protein Assay kit (Thermo scientific, Waltham, MA) using BSA as a standard and 
samples with equal protein concentrations were denatured by boiling in Laemmli buffer. 
Polypeptides were resolved by SDS-PAGE and transferred onto a PVDF membrane. The 
membrane was blocked with 5% BSA in Tris-buffered saline with Tween20 (20 mM Tris 
[pH 7.4], 137 mM NaCl, and 0.1% Tween20) overnight at 40C and probed with specific 
primary and secondary antibodies. Proteins were detected using chemiluminiscent HRP 
substrate (Millipore, Billerica, MA). The membrane was kept in stripping buffer for 10 
min and re-probed using anti-β-actin antibody. The antibodies used were rat anti-
sVEGFR-1-1 (141515; R&D Systems), mouse anti-VEGF-A (EE02; Santa Cruz 
Biotechnology, Santa Cruz, CA), mouse anti MMP-2 (8B4; Santa Cruz Biotechnology, 
Santa Cruz, CA), goat anti mouse MMP-8 (M-20; Santa Cruz Biotechnology, Santa Cruz, 
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CA), goat anti mouse MMP-9 (C-20; Santa Cruz Biotechnology, Santa Cruz, CA), goat 
anti mouse MMP-12 (M-19; Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-β-
actin (AC74; Sigma-Aldrich, St Louis MO), goat anti rat IgG-HRP (R & D Systems), 
goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) and donkey anti goat IgG-HRP 
(Santa Cruz Biotechnology). 
Coimmunoprecipitation. Coimmunoprecipitation was performed using Pierce 
Coimmunoprecipitation kit according to manufacturer’s protocol (Thermo Scientific). 
Briefly, 50 µg of anti sVEGFR-1-1 antibody was immobilized to antibody coupling resin 
by incubating the antibody to resin containing column for 2 hrs at room temperature. 
Care was taken to keep resin slurry in suspension during incubation. The 200 µl 
supernatant from lysed corneal cells (800 µg of total protein) was incubated for 2 hrs at 
4oC with the above mentioned resin immobilized antibody. Finally, 50 µl of the elution 
buffer was added and immunoprecipitate was eluted out and analyzed by WB. 
ELISA. The pooled corneal samples were homogenized using a tissue homogenizer and 
supernatant was used for analysis. The concentrations of VEGF-A and sVEGFR-1-1 
were measured using Quantikine sandwich ELISA kits (R&D Systems) according to 
manufacturers protocol. 
Quantification of total number of molecules for sVEGFR-1 and VEGF-A. The total 
number of sVEGFR-1 and VEGF-A molecules from naïve as well as different day pi 
samples were calculated using following formula. 
Total Number of Molecules = Quantity of Protein × Molecular Weight × Avogadro’s No. 
In vitro assay for VEGF‐A and sVEGFR-1‐1 production. A mouse stromal fibroblast 
cell line (MK/T-1) was used to study differential effect of HSV-1 on production of 
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VEGF-A and sVEGFR-1-1. The cells were cultured and plated onto 6-well tissue culture 
plates in 10% DMEM. The cells around >90% confluents were infected with HSV-KOS 
at 3 multiplicity of infection (MOI) (adsorbption for 1 h). Uninfected cells were used as 
control. Cells were harvested at different time points and total mRNA was extracted and 
used to quantify the mRNA levels of the VEGF-A and sVEGFR-1-1. 
Degradation assays. Degradation assays were performed as previously described (19). 
Briefly, 100 ng of rsVEGFR-1-1 (R&D Systems) was incubated with active mouse 
MMP-2, MMP-7, MMP-8, MMP-9 and MMP-12 (R&D Systems), at 1:1 
substrate/enzyme molar ratio at 37°C for 24 hours. Pro-MMPs were activated by p-
aminophenylmercuric acetate (Sigma-Aldrich) before use according to manufacturer’s 
protocol. To study the degradation of mouse native sVEGFR-1-1 from cornea, the 
supernatant from lysed corneal cells was collected and incubated with different activated 
MMPs [1:1 substrate enzyme molar ratios] at 37°C for 24 hours. MMP activity was 
inhibited using 20 mM ethylenediaminetetraacetic acid (EDTA). The samples were then 
analyzed by WB. 
Statistics. Student’s t test was performed to determine statistical significance and data are 




Presence of VEGF-A in ocular tissues of normal mice 
 
Recently, it was demonstrated that VEGF-A is present in normal corneal tissues, 
but it fails to induce angiogenesis because it is bound to sVEGFR-1-1 (15). Both VEGF-
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A and sVEGFR-1-1 are produced continuously by normal ocular tissues. As a prelude to 
measuring the influence of HSV-1 ocular infection on the balance between VEGF-A and 
sVEGFR-1-1, we repeated some of the normal mice experiments previously described 
(15). We were able to confirm many of their observations. Accordingly, as shown in 
Figure-1, corneal extracts from naïve mice analyzed by WB under reducing conditions 
revealed a band of 62kDa for sVEGFR-1-1 and two bands for VEGF-A at molecular 
sizes of 22 and 14 kDa (Figure 3.1A). These bands correspond to two isoforms of VEGF-
A. However, under non-reducing conditions, blots revealed only a single band that was 
far larger than those observed in reducing gels and had an apparent size of between 100-
150 kDa (Figure 3.1B). This would be consistent with VEGF-A being bound to another 
molecule, presumably sVEGFR-1-1. Support for this was obtained performing co-
immunoprecipitation that revealed the interaction of VEGF-A and sVEGFR-1-1 (Figure 
3.1C). 
The fact that normal ocular tissue expressed mRNA for both the VEGF-A and the 
sVEGFR-1-1 proteins was also demonstrated by RTPCR (Figure 3.1D). The sVEGFR-1-
1 molecule was also readily detectable in epithelial and stromal layers of corneal sections 
by immunohistochemistry (Figure 3.1E). Our findings are consistent with and confirm 
those reported by the Ambati group and demonstrate that VEGF-A is present in cornea 
and is mostly bound to sVEGFR-1-1 forming a so called VEGF-A trap (15, 20-21). 
 
Changes in VEGF-A and sVEGFR-1-1 as a consequence of HSV-1 infection 
 
The principal objective of our study was to evaluate if the VEGF-A trap affected 
the outcome of pathological angiogenesis caused by ocular infection with HSV-1. To do 
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this, mice were ocularly infected with virus and the expression levels of both VEGF-A 
and sVEGFR-1-1 mRNA and proteins were measured and compared with controls at 
various times pi. We focused on initial time points after infection when replicating virus 
is readily detectable in the cornea (up to 5 day pi) as well as at the stage of clinical SK 
(day 8 pi) when replicating virus is no longer demonstrable and the stroma is heavily 
infiltrated by inflammatory cells, particularly neutrophils (4, 22). At each time point, 6 
corneas were collected and pooled for analysis from infected and control animals by 
QPCR. The data expressed in Figure 3.2A records average gene expression values 
compared with controls for 2 separate experiments. As is evident, increased VEGF-A 
expression (6.7 fold) was detectable by 24 hours pi and levels peaked in the early phase 
(average 11.5 fold) in samples tested on days 2 pi. By day 5, VEGF-A mRNA expression 
levels were at control levels. However, VEGF-A mRNA levels increased in later samples 
with the highest levels detectable (average 97 fold) in day 11 samples. At day 11, 
replicating virus and viral mRNA were no longer present in corneal extracts (data not 
shown) and the VEGF-A that was detected was presumed to be produced mainly by 
infiltrating inflammatory cells such as neutrophils (described subsequently). 
The general pattern observed measuring VEGF-A gene expression was evident 
with protein levels measured by ELISA and WB. As shown in Figure 3.2B and 3.2C, 
after an initial peak of VEGF-A protein on days 2 to 3 pi, a second higher peak was 
observed during the clinical phase. The non-reducing WB of corneal extracts from naïve 
mice revealed single high molecular weight band for VEGF-A (presumably all bound to 
sVEGFR-1). However, corneal extracts from day 3 pi showed another low molecular 
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weight band for VEGF-A suggesting the presence of non sVEGFR-1 associated free 
VEGF-A after HSV-1 infection (Figure 3.2D). 
Quantification of sVEGFR-1-1 gene expression revealed a different response 
pattern than was noted with VEGF-A (Figure 3.2E). The expression levels were 
decreased following HSV-1 infection with maximal decreases observed in samples taken 
at 5 days pi (average 8 fold compared to control). The initial decreased expression of 
sVEGFR-1-1 could reflect the well known ability of HSV to suppress almost all host 
gene expression in cells in which it replicates (23, 24). However, VEGF-A gene 
expression, at least early after infection, may be an exception as are some cytokines (13, 
25, 26). To determine if HSV infection could differentially influence the expression of 
VEGF-A and sVEGFR-1, we studied the outcome of in vitro infection of an eye derived 
cell line (MK/T-1) that spontaneously expressed both VEGF-A and sVEGFR-1 
(Supplemental Figure 3.1A). This cell line was derived from corneal stromal fibroblasts. 
The results demonstrate that early after HSV-1 infection whereas VEGF-A levels were 
increased, levels of sVEGFR-1 mRNA were markedly suppressed (Supplemental Figure 
3.1B). Although fibroblasts are not the major cell type infected by HSV in vivo, our 
results imply that a similar outcome could occur in corneal epithelial cells, the primary 
target cells for HSV infection.  
Experiments were also done to quantify protein levels at various time points by 
ELISA. In corneal extracts of uninfected animals, sVEGFR-1-1 protein was readily 
detectable, and these levels were far higher than VEGF-A in the same samples (Figure 
3.2F). Changes in sVEGFR-1-1 protein levels detectable by ELISA did occur at different 
time points after infection, and significant reduction in the levels of sVEGFR-1 were 
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observed on day 1 and from day 5 to 11 pi. Additionally, when the ratio of the number of 
sVEGFR-1 molecules to VEGF-A molecules from naïve mice was compared with 
infected animals at various time points pi, there was a decreased ratio of sVEGFR-1 to 
VEGF-A at all time points pi. Differences were significant on day 1 as well as from day 7 
to 14 pi (Figure 3.2G). Furthermore, an interesting situation was revealed by WB analysis 
under reducing conditions of samples taken at different time point pi (Figure 3.2H). Here 
it was evident in corneal extracts from uninfected animals that sVEGFR-1-1 protein was 
represented almost entirely as a single band at approximately 60 kDa size. However, by 
day 3 pi, there was notable fragmentation of the sVEGFR-1-1 and this situation was also 
evident in samples collected at other time points after infection. The degradation of 
sVEGFR-1 could explain why we observed minimal sVEGFR-1 protein at day 11-time 
point even though sVEGFR-1 mRNA levels peaked at this time. These observations led 
us to conclude that HSV infection of the cornea diminished the expression of sVEGFR-1-
1 and that the intact protein was degraded, at least partially, at different phases of virus 
infection. Both effects would serve to diminish the inhibitory activity of sVEGFR-1-1 on 
VEGF-A induced angiogenesis. 
An additional series of experiments supported the notion that the activity of 
sVEGFR-1-1 has a constraining effect on the angiogenic activity of VEGF-A. We 
anticipated that the provision of an additional exogenous source of sVEGFR-1-1 protein 
to HSV-1 infected mice might act to diminish the extent of angiogenesis that occurs 
subsequent to infection. To evaluate this possibility, we obtained recombinant mouse 
sVEGFR-1-1 (rsVEGFR-1-1) fusion protein that had previously been used by others to 
counteract VEGF-A activity in a VEGF-A induced micro-pocket assay for angiogenesis 
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(15). In our pathological system, we chose to administer a higher dose rsVEGFR-1-1, or 
an isotype fusion protein (Isotype). To evaluate the possible VEGF-A inhibitory effects 
in vivo, animals were given either rsVEGFR-1-1 or Isotype subconjunctivally to HSV-1 
infected animals, either starting at day 1 (Figure 3.3A) or day 7 pi (Figure 3.3E). Animals 
were followed until day 15 pi to measure the extent of angiogenesis. Results shown in 
Figure 3.3A-C and Supplemental Figure 3.2A indicated that rsVEGFR-1-1 recipients had 
significantly diminished angiogenic responses as well as SK lesion severity compared to 
the isotype group. Corneal cell preparations collected at the end of the experiment 
revealed diminished frequency and numbers of CD31+ (a marker for blood vessel 
endothelial cells), neutrophils as well as CD4+ T cells (Figure 3.3D and Supplemental 
Figure 3.2B). It is of particular interest to note that even when rsVEGFR-1-1 
administration was delayed till day 7 pi (Figure 3.3E), a significant level of SK severity 
and angiogenesis inhibition was still evident. These results further support the concept 
that sVEGFR-1-1 may limit the angiogenic response to VEGF-A in pathological 
angiogenesis. 
 
Metalloproteinases could be responsible for sVEGFR-1-1 degradation 
 
The observation that sVEGFR-1-1 protein may be degraded in HSV-1 infected 
corneas raised the question of how the breakdown was accomplished. Likely enzyme 
candidates include MMPs, some of which were shown to be present in damaged eyes in 
other systems (1). Previous reports suggest that MMP-9 could induce neovascularization 
in vivo and inhibition of MMP-9 reduces angiogenesis (27).  Moreover, MMP-9 protein 
is present in the cornea following HSV-1 infection as we have reported previously (28). 
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Experiments were performed to measure the expression profile by QPCR of several 
MMP mRNAs at various time points after HSV-1 infection. The results shown in Figure-
3.4A demonstrate that compared to uninfected controls, expression levels of several 
MMPs were elevated following the infection. Peak levels that varied between 
experiments differed between the MMPs tested, but always occurred between days 5 and 
days 11 pi. Of the multiple MMP mRNAs examined, expression levels of MMP-9 were 
the most elevated with its peak evident in day 7 pi samples (Average 249 fold). Another 
MMP of interest was MMP-7 since this enzyme was shown recently to be uniquely 
capable degrading human sVEGFR-1-1 (19). Levels of MMP-7 were at their peak on day 
11 pi. Additional experiments were done in vitro with the activated form of selected 
MMPs (MMP-2, MMP-7, MMP-8, MMP-9, and MMP-12) to measure their ability to 
degrade rsVEGFR-1-1 in vitro as detected by WB. As is evident in Figure 3.4B, MMP-7 
was most effective at degrading rsVEGFR-1-1 with MMP-9 also active, but less so. In 
these assays, MMP-8 and MMP-12 were without activity and MMP-2 had a minimal 
effect. In additional experiments, MMP-2, MMP-7 and MMP-9 were shown to degrade 
sVEGFR-1-1 present in naïve corneal extracts (Figure 3.4C).  
Experiments were also done to determine if inhibiting the function of MMP 
enzymes in vivo affected sVEGFR-1-1 degradation, as well the outcome on the extent of 
angiogenesis and SK severity. To accomplish MMP inhibition, marimastat (29-31) was 
administered subconjunctivally at different times pi and the results compared to infected 
mice given subconjunctival injections of mock. In an experiment in which animals 
received marimastat on days 2,4 and 6 pi, corneal extracts examined by WB on day 7 pi 
revealed a markedly reduced level of sVEGFR-1-1 degradation compared to controls 
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(Figure-3.5A). In another experiment, two marimastat injections given on days 2 and 4 
also revealed inhibited sVEGFR-1-1 degradation in samples examined on day 5 (Data not 
shown). 
When the outcome of angiogenesis and SK severity was compared in treated and control 
mice, the marimastat recipients had significantly reduced levels of angiogenesis and SK 
severity, at least at day 15 pi time point when experiments were terminated (Figure 3.5B). 
Corneal cell preparations collected at the end of the experiment revealed diminished 
frequency and numbers of CD31+ endothelial cells, neutrophils and CD4+ T cells (Figure 
3.5C and Supplemental Figure 3.3A). Furthermore, in an experiment in which marimastat 
treatment was begun on day 5 pi and given additional injections on days 7, 9 and 11 there 
was also a significant reduction of angiogenesis and lesion scores at day 15 pi (Figure 
3.5D). Corneal cell preparations collected at the end of the experiment revealed 
diminished frequency and numbers of CD31+ endothelial cells, neutrophils as well as 
CD4+ T cells (Figure 3.5E and Supplemental Figure 3.3B). Taken together our results 
support the concept that metalloproteinases, particularly MMP-2, MMP-7 and MMP-9, 
are upregulated following HSV-1 infection and these enzymes are responsible for 
degrading the sVEGFR-1-1 protein that, in turn, constrains the angiogenic activity of 
VEGF-A. 
 
Neutrophils play multiple roles in ocular angiogenesis 
 
A prominent cell type in the inflammatory response to ocular HSV-1 infection is 
the neutrophil (8, 13, 22). To investigate the role played by neutrophils in HSV-1 
mediated corneal angiogenesis, kinetic studies were carried out for neutrophil infiltration 
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in the cornea following HSV infection. As shown in Figure 3.6A, neutrophils constitute 
about 30-80% of total infiltrated leukocytes at all tested time points and infiltrate the 
cornea in a biphasic manner. An initial wave of infiltration peaked around day 2 pi 
followed by decline and second wave starting from day 8 till which peaked around day 
15 pi (Figure 3.6B). Since, neutrophils studied in other systems are known to be a source 
of different MMPs as well as VEGF-A (28, 32-34); we anticipated that neutrophils could 
be a source of MMP enzymes that act to increase angiogenesis by breaking down and 
releasing bioactive VEGF-A from its bond to sVEGFR-1-1. In support of this, we 
purified neutrophils from the day 2 infected corneas and WB analysis was carried out to 
check the presence of protein for MMP-2, MMP-8, MMP-9 and MMP-12. Figure 3.6C 
shows the presence of MMP-2, MMP-8, MMP-9 and MMP-12. Additionally, depleting 
neutrophils from day 7 pi (Figure 3.6D) in infected mice led to significantly diminished 
VEGF-A protein levels and restored levels of sVEGFR-1-1 protein in day 11 samples 
(Figure 3.6E). QPCR analysis also revealed the decreased expression of VEGF-A and 
MMP-9 in the depleted mice as compared to isotype antibody treated mice (Figure 3.6F). 
To further implicate neutrophils as a source of VEGF-A during the clinical phase of SK, 
neutrophils were purified from pooled corneas at day 11 pi and RTPCR and WB carried 
out to check for the presence of VEGF-A mRNA message as well as protein. Both 
VEGF-A mRNA (Figure 3.6G) and protein (Figure 3.6H) could be demonstrated 
supporting a role for neutrophils in contributing to angiogenesis during the clinical phase 
of SK when replicating virus is no longer present in the cornea.   
  To show the influence of neutrophils during HSV-1 induced pathological 
angiogenesis, experiments were done to compare the extent of angiogenesis and 
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differences in expression levels of VEGF-A and sVEGFR-1-1 in mice depleted of 
neutrophils compared to controls. Depletion (with anti-Gr1 MAb) was commenced on 
day 7 pi. As shown in Figure 3.6I, whereas the extent of angiogenesis and SK lesion 
severity continued to increase in magnitude in isotype antibody treated animals, by day 
15 pi, when the experiment was terminated, the average angiogenic response and SK 
severity were significantly decreased in animals treated with neutrophil depleting 
antibody. Although, cell types in inflammatory reaction other than neutrophils can 
express Gr1, neutrophils are the predominant Gr1+ population in lesion during clinical 
phase of SK. We interpret Gr-1 depletion experiment where the VEGF-A levels were 
decreased to mean that neutrophils represent a major source of the VEGF-A that is 
involved in HSV-1 induced angiogenesis even though a minority of other cell types in 
inflammatory reaction can also be Gr1+. Taken together these results demonstrate that 
neutrophils contribute to the severity of the pathological angiogenic response caused by 
HSV-1 infection. This occurs because neutrophils, can act as one of the sources of 
VEGF-A as well as the MMP enzymes that degrade sVEGFR-1-1, the molecule that 
binds to VEGF-A and inhibit its angiogenic activity. 
 
Discussion 
In this report, we investigate mechanisms by which HSV-1 infection of the eye 
results in neovascularization, an essential step in the pathogenesis of SK, an ocular lesion 
that impairs and can ablate vision (35). We confirm a previous report (15) that VEGF-A, 
a principal angiogenic factor, is produced by the normal eye, but is constrained from 
causing angiogenesis by being bound to a soluble form of one of its cellular receptors. 
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Our results make the novel observation that one consequence of HSV-1 infection is to 
cause an imbalance in the production of VEGF-A and sVEGFR-1-1 that impedes its 
activity. Whereas, the infection up-regulates VEGF-A production, the expression of 
sVEGFR-1-1 is inhibited. Moreover, the sVEGFR-1-1 protein that is made is degraded 
by the metalloproteinase enzymes MMP-2, -7 and -9 which permits the VEGF-A, 
initially derived from infected epithelial cells, and later on inflammatory cells, to exert 
more effective angiogenic activity. Procedures that decrease the breakdown of sVEGFR-
1-1, such as the administration of the MMPi, marimastat, or the provision of exogenous 
rsVEGFR-1-1 protein resulted in lessened angiogenesis. Our results support the notion 
that the binding of sVEGFR-1-1 to VEGF-A, a so called VEGF-A trap, acts to limit the 
extent of pathological angiogenesis such as that caused by ocular infection by HSV-1. It 
is also conceivable that future therapies to control SK could benefit by procedures that 
influence the production and activity of the sVEGFR-1-1. Our overall results are 
summarized in Figure-3.7, showing how HSV-1 infection leads to corneal angiogenesis. 
The pathogenesis of SK involves multiple events that include neovascularization 
of the normally transparent tissue anterior to the retina. Thus any new blood vessel 
development in the anterior tissues damages vision by defracting light and, since new 
vessels are leaky (4, 11), they readily permit escape of inflammatory cells that further 
contribute to the loss of transparency. Accordingly, preventing, and ideally reversing, 
neovascularization is an important objective to retain optimal vision. Numerous 
mechanisms have been suggested to explain how HSV infection could cause 
neovascularization (8, 28, 36), but perhaps the most important is the induction of VEGF 
family members, especially VEGF-A which stimulates corneal angiogenesis by engaging 
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the receptor VEGFR-2 (8, 10). Supporting this, prior studies have shown that 
counteracting the VEGF-A made or inhibiting its receptor can significantly reduce HSV 
induced angiogenesis (8, 10). Others, as well as ourselves, have already reported that 
HSV infection of the corneal epithelium in the early stages of keratitis results in the 
expression of VEGF-A protein either in infected or nearby cells (13, 14). What we had 
not appreciated, until the observations of the Ambati group appeared (15), is that VEGF-
A is continually produced by uninfected normal eyes but fails to cause corneal 
vascularization because the VEGF-A is bound to a soluble form of one of its receptors 
(15). The important aspect of our study is our observations that the binding of sVEGFR-
1-1 to VEGF-A made during a pathological disease process may also act to modulate 
VEGF-A activity and influence the magnitude of angiogenesis. A series of observations 
led to this conclusion. 
Firstly in the early stages after HSV infection much of the VEGF-A detected by 
WB under native conditions was of a molecular size consistent to its being bound to 
another protein that was shown to be sVEGFR-1-1. Of interest, soon after infection one 
consequence of HSV-1 was to exert a differential effect on gene expression of VEGF-A 
and sVEGFR-1-1 proteins. Accordingly, whereas infection caused an increased 
expression of VEGF-A, the production of the sVEGFR-1-1 was inhibited. Additionally, 
that infection of cells could enhance VEGF-A, but suppress sVEGFR-1-1, gene 
expression could also be shown by in vitro studies. Thus the initial angiogenesis observed 
after infection could be the consequence of enhanced VEGF-A activity arising both from 
increased production as well as diminished inhibition. In support of the latter mechanism, 
if an additional exogenous source of sVEGFR-1-1 was provided during the early stages 
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of the disease process, the outcome was diminished angiogenesis. These observations 
taken together support the idea that a VEGF-A trap operates to limit the extent of 
pathological angiogenesis at least early after infection. 
It is characteristic of HSV-1 ocular infection in the mouse model that the virus is 
cleared within a few days, but the extent of angiogenesis continues to advance as does the 
chronic inflammatory process in the corneal stroma that is indicative of SK (4, 8). Our 
studies show that VEGF-A may also be responsible for the additional angiogenesis but 
the principal cell source of the VEGF-A is no longer the epithelium (that is no longer 
infected) but instead derives from invading inflammatory cells, particularly neutrophils. 
We could show that depleting Gr1+ cells with specific mAb on day 7 pi diminished the 
extent of the neovascular response compared to non-depleted controls indicating their 
role in VEGF-A production. Depleted animals also had less VEGF-A protein in corneal 
extracts when quantified by ELISA. However, we anticipated that at the later phases of 
the disease process, the activity of VEGF-A was less likely to be impeded by its binding 
to the sVEGFR-1-1 protein. Thus, in addition to being a source of VEGF-A the invading 
inflammatory cells are well known to produce many different MMP enzymes (28, 37) 
some of which could degrade proteins that bind to VEGF-A and limit its activity (34). 
For example, in some cancer systems where VEGF-A is shown to be bound to a matrix 
protein, MMP-9 may degrade the matrix protein so releasing VEGF-A to exert 
angiogenic activity (38). Moreover, VEGF-A processed by different MMPs retains 
biological activity (39).  Also of relevance, MMP-7 was shown very recently to degrade 
human sVEGFR-1-1 resulting in increased angiogenic activity in an in vitro tube 
formation assay using human umbilical vein endothelial cells (19). In our present study, 
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we could demonstrate that the inflammatory exudate cells could express several MMPs 
and that at least two of them (MMP-7 and MMP-9) were highly effective in vitro at 
degrading the mouse sVEGFR-1-1 protein, that had not previously been reported. We 
could show the effect using a recombinant sVEGFR-1-1 protein as well as with 
sVEGFR-1-1 preparations isolated from normal mouse corneas. However, of special 
relevance to our viewpoint as the constraining role of sVEGFR-1-1 on VEGF-A activity, 
we could clearly demonstrate that if we treated animals with marimastat, an inhibitor of 
MMP enzyme activity, then the extent of the neovascular response was significantly 
diminished compared to untreated animals. Furthermore, WB revealed that sVEGFR-1-1 
protein concentrations were higher in marimastat treated corneal samples. 
Taken together we contend that our studies have provided novel insight on 
mechanistic aspects of SK pathogenesis and have revealed a previously unrecognized 
event that could be targeted for therapeutic manipulation. Accordingly, we show that the 
important event of ocular angiogenesis mediated by VEGF-A is markedly influenced by 
the presence and activity of the sVEGFR-1-1 protein. When bound to sVEGFR-1-1, as 
occurs with all of the VEGF-A made by the normal cornea, VEGF-A is unable to 
mediate angiogenesis. In a pathological situation this VEGF-A trap is also occurring, but 
it breaks down when levels of MMPs arrive that can degrade the sVEGFR-1-1 protein 
(Fig 7). It would seem logical to develop therapies to manage SK that either increase the 
concentration or retard the breakdown of the sVEGFR-1-1 protein. Further studies are 
underway to investigate this issue. 
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FIGURE 3.1. NORMAL CORNEA EXPRESSES VEGF-A BOUND TO SVEGFR-1.  
WT mice were sacrificed and 4 to 6 corneas were collected and pooled for WB, 
Co-immunoprecipitation, and mRNA analysis by RTPCR. Data are representative of two 
independent experiments. (A) Reducing WB analysis for sVEGFR-1 and VEGF-A 
reveals presence of sVEGFR-1 at 62 kDa and two isoforms of VEGF-A at 22 and 16 kDa 
in normal cornea. (B) Non-reducing WB for VEGF-A shows the presence of a much 
larger band between molecular size of 100 to 150 kDa consistent with its being the bound 
form. (C) sVEGFR-1 was immunoprecipitated from normal corneal extracts, with anti 
sVEGFR-1 mAb and the complex was analyzed for the co-immunoprecipitation of 
VEGF-A by WB. Normal cornea shows the presence of VEGF-A bound to sVEGFR-1. 
(D) Agarose gel analysis of VEGF-A (214bp) (lane 3) and sVEGFR-1 (358bp) (lane 5) 
cDNA from normal uninfected cornea. Lane M-marker, lane 1- β-actin (92bp), lane 2, 4 
and 6 are reverse transcriptase negative controls for β- actin, VEGF-A and sVEGFR-1. 
(E) Representative immunofluorescence staining of corneal section for sVEGFR-1 
(green, left panel), nuclei (blue, middle panel) reveals the presence of sVEGFR-1 mainly 
in the corneal epithelial layer and to a lesser extent in the stroma (Merge). Nuclei were 
stained (blue) with DAPI. Image is representative of two independent experiments. 
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FIGURE 3.2 CORNEAL HSV-1 INFECTION CAUSES AN IMBALANCE BETWEEN VEGFA 
AND SVEGFR-1.  
WT mice corneas were scarified and infected with 104 PFU of HSV in PBS or 
mock infected with only PBS (naïve control mice). Corneas were harvested from infected 
mice at indicated time points PI and from naive control mice at 24 hr. (A) At each time 
point 6 corneas were collected and pooled for mRNA extraction. The expression levels of 
VEGF-A molecule were normalized to β-actin using ΔCt calculation. Relative expression 
between control and infected groups were calculated using the 2–ΔΔCt formula. Kinetic 
analysis for the expression of VEGF-A mRNA by quantitative PCR (QPCR) at different 
days pi. The expression of VEGF-A shows a biphasic upregulation pattern, early on day 2 
pi and then again on day 11 pi as compared to naïve cornea. Figure is a summary of two 
independent experiments and each experiment represent group of 6 corneas.  (B) At each 
time point 6 corneas were harvested from infected or naïve mice and the levels of VEGF-
A were determined by ELISA. Quantification of VEGF-A protein levels in the normal 
and infected corneas at different days pi reveals similar pattern as that of gene expression. 
Figure is a summary of at least two independent experiments and each experiment 
represent group of 6 corneas. P ≤ 0.009 (**), P = 0.0004 (***). (C) At each indicated 
time points 3-4 corneas were harvested and total protein concentration were measured by 
BCA protein assay. Samples with equal protein concentration were subjected to SDS-
PAGE followed by WB analysis. VEGF-A expression was analyzed by WB analysis 
showed an increase in the VEGF-A protein levels at different days pi compared to naïve 
control mice. (D) Three to four corneas were harvested from day 3 pi or naïve control 
mice at 24 hr pi. Samples with equal protein concentration were subjected to native-
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PAGE followed by WB analysis. The left figure shows a band of molecular size between 
100 to 150 kDa in naïve corneal sample. The right is from day 3 infected corneas. It 
shows the large 100-150 kDa band as well as another at 50 kDa indicating the presence of 
both bound and free VEGF-A.  (E) Kinetic analysis for the expression of sVEGFR-1 
mRNA by QPCR at different days pi. Relative change in the expression of sVEGFR-1 
mRNA at different days pi as compared to the uninfected mice revealed a sharp decrease 
in the sVEGFR-1 expression from day 3 pi which reached above normal around day 11 pi 
and back to normal levels at day 14 pi. The figure is a summary of two independent 
experiments and each experiment represent group of 6 corneas. (F) sVEGFR-1 protein 
levels analyzed by ELISA from the normal and infected corneas at different days pi 
shows an early decrease after HSV-1 infection which reaches to level found in normal 
controls at day 14 pi. The figure is a summary of at least two independent experiments 
and each experiment represent group of 6 corneas. P ≤ 0.05 (*), P = 0.0023 (**), P ≤ 
0.0001 (***). (G) Quantification of total number of sVEGFR-1 molecules per VEGF-A 
molecule from naïve and infected corneas at different days pi using protein quantities 
obtained by ELISA (B & F) shows the significant reduction of total number of sVEGFR-
1 molecules per VEGF-A molecule on day 1 and from day 7 to 14 pi. The total number of 
molecules for sVEGFR-1 and VEGF-A were calculated by multiplying the total quantity 
of the protein by its molecular weight and Avogadro’s number. The figure is a summary 
of values obtained from figure B and F. P = 0.0216 (*), P ≤ 0.0032 (**), P ≤ 0.0002 
(***). (H) Reducing WB analysis for sVEGFR-1 from uninfected and infected corneas at 
different time pi shows degradation of sVEGFR-1 after HSV-1 infection. Degraded 
products are shown by black arrowhead. 
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FIGURE 3.3. RSVEGFR-1 ADMINISTRATION HINDERS ANGIOGENIC ACTIVITY OF VEGF-
A AND INHIBITS CORNEAL ANGIOGENESIS POST HSV-1 INFECTION.   
WT mice were ocularly infected by corneal scarification with 104 PFU of HSV. 
(A) rsVEGFR-1 or isotype Fc protein were administered subconjunctivally at 5 µg/eye as 
shown.  The extent of angiogenesis and SK lesion severity in the eyes of HSV infected 
mice were quantified in a blinded manner using a scale as described in materials and 
methods. The progression of angiogenesis and SK lesion severity were significantly 
reduced in the group of mice treated with rsVEGFR-1 as compared to isotype treated 
mice. Data are representative two independent experiments (n = 10-12 mice/group).  P ≤ 
0.0007 (***). (B) Representative whole mount corneas stained for CD31 (lower panel) at 
day 15 pi shows reduced angiogenic response in rsVEGFR-1 treated mouse. Bars, 
100µm. (C) Representative eye photos shows reduced SK lesion severity as well as 
angiogenesis from rsVEGFR-1 treated mouse compared to isotype treated mouse. (D) 
rsVEGFR-1 or isotype Fc protein treated mice were sacrifice on day 15 pi and corneas 
were collected for surface staining of eye infiltrating cells.  Total cell numbers per cornea 
for CD31+ cells, Neutrophils (CD11b+, Ly6G+ cells) gated on total CD45+ cells and CD4+ 
T cells showed the significant reduction in total numbers of the respective cell population 
from rsVEGFR-1 treated mice as compared to the isotype treated mice. Data are a 
representative of two independent experiments (n = 3-5/group). P = 0.012 (*), P ≤ 0.0015 
(**). (E) Therapeutic administration of the rsVEGFR-1 was started from day 7 pi when 
SK becomes visibly evident. Therapeutic administration of rsVEGFR-1 also showed 
significant reduction in angiogenesis as well as lesion severity further confirming the 
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inhibitory effect of sVEGFR-1 on the angiogenic activity of VEGF-A. Data are a 
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FIGURE 3.4. METALLOPROTEINASES ARE UPREGULATED AFTER HSV-1 INFECTION AND 
MMP-2, 7 AND 9 DEGRADES RSVEGFR-1 AND SVEGFR-1.  
(A) WT mice corneas were scarified and infected with 104 PFU of HSV in PBS or 
mock infected with only PBS (naïve control mice). Corneas were harvested from infected 
mice at indicated time points PI and from naive control mice at 24 hr. At each time point 
6 corneas were collected and pooled for mRNA extraction. The expression levels of 
different MMP molecule were normalized to β-actin using ΔCt calculation. Relative 
expression between control and infected groups were calculated using the 2–ΔΔCt formula. 
Kinetic analysis for the relative fold change in the expression levels of MMP- 2, MMP-7, 
MMP-8, MMP-9 and MMP-12 mRNAs at different days pi. The mRNA expression of all 
the tested MMPs was upregulated in biphasic manner post HSV-1 infection with the first 
peak expression at day 1 pi and maximum expression between day 7 and day 11 pi. (B) 
Mouse rsVEGFR-1 was incubated with activated form of MMP-2, MMP-7, MMP-8, 
MMP-9 and MMP-12 for 12 hrs at 370C and analyzed by WB. MMP-7 (lane 3) showed 
maximum degradation of rsVEGFR-1 followed by MMP-9 (lane 5) and MMP-2 (lane 2). 
Addition of the MMP inhibitor, EDTA, inhibited the degradation of rsVEGFR-1 by 
MMP-7 (lane 7) and MMP-9 (lane 8). Figure is a representative of three independent 
experiments. (C) Corneal lysates from 4-6 pooled corneas of uninfected WT mice were 
incubated with activated form MMP-2, MMP-7, MMP-8, MMP-9 and MMP-12 either for 
6 hr or 12 hr at 370C. The digested corneal lysates were analyzed by WB for sVEGFR-1. 
MMP-7 showed degradation of corneal sVEGFR-1 even after 6 hrs of incubation (upper 
panel, lane 2), with complete degradation after 12 hrs of incubation (lower panel, lane 2). 
MMP-2 (lower panel, lane 1) and MMP-9 (Lower panel lane 4) also showed degradation 
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of corneal sVEGFR-1 after 12 hrs of incubation. Addition of MMP inhibitor EDTA with 
MMP-7 (lane 6) showed inhibition of sVEGFR-1 degradation. Figure is a representative 
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FIGURE 3.5. BLOCKING MMPS ACTIVITY IN VIVO RESCUES SVEGFR-1 DEGRADATION 
AND DIMINISHES ANGIOGENESIS AND SK SEVERITY.  
WT mice corneas were scarified and infected with 104 PFU of HSV or mock 
infected with only PBS (naïve control mice). Marimastat, a broad-spectrum MMP 
inhibitor (MMPi) was administered subconjunctivally at 200 ug/mouse as shown. Mice in 
control group received HSV infection with mock treatment. (A) WB analysis of the 
corneal lysates collected from naïve (N), control treated (C) and MMPi treated mice at 
day 7 pi shows that MMPi rescues degradation of sVEGFR-1 post HSV-1 infection. The 
figure is a representative of two independent experiments. (B) Preventive treatment of 
MMPi in mice infected with HSV-1 was started from day 2 pi as shown. MMPi treatment 
showed a significant reduction of angiogenesis as well as SK lesion severity at day 15 pi. 
Data are representative of two independent experiments (n = 9-12 mice/group). P ≤ 0.04 
(*), P = 0.0065 (**). (C) MMPi treated or control mice were sacrifice on day 15 pi and 
corneas were collected for surface staining of eye infiltrating cells. Analysis for total cell 
numbers per cornea for CD31+ cells, neutrophils (CD45+ CD11b+ Ly6G+ cells) and CD4+ 
T cells showed significant reduction in frequencies as well as total numbers of the 
respective cell population in the MMPi treated mice. Data are a representative of two 
independent experiments (n = 7/group). P = 0.0115 (*), P = 0.0078 (**), P = 0.0002 
(***). (D) Therapeutic administration of the MMPi (started from day 5 pi), also showed 
reduced angiogenesis as well as SK lesion severity at day 15 pi. Data are a summary of 
two independent experiments (n = 6 mice/group). P ≤ 0.021 (*). (E) Analysis of total cell 
numbers per cornea for CD31+ cells, neutrophils (CD45+CD11b+, Ly6G+ cells) and CD4+ 
T cells also showed the significant reduction in the total cell numbers per cornea after 
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preventive MMPi treatment. Data are a representative of two independent experiments (n 
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FIGURE 3.6. NEUTROPHIL, THE PRINCIPAL CELL IN CORNEA AFTER HSV-1 INFECTION IS 
SOURCE OF MMPS AND  VEGF-A.  
WT mice corneas were scarified and infected with 104 PFU of HSV or mock 
infected with only PBS (naïve control mice). At each indicated day pi two mice were 
sacrificed, corneas were harvested and single cell suspensions were analyzed for surface 
staining by flow cytometry. (A) Representative FACS plot from each time point shows 
the percentage of neutrophils (CD11b+Ly6G+) gated on total CD45+ cells. (B) Total 
number of neutrophils per cornea at each indicated time point post HSV-1 infection. Data 
are expressed as mean ± SEM. Figure is a summary of two independent experiments and 
each experiment represent group of 2 corneas. (C) Ly6G+ neutrophils were purified from 
day 2 pi corneas using anti-Ly6G beads. Cell suspension from 6-8 pooled corneas was 
used for neutrophil purification. Western blot analysis for MMP-2, MMP-8, MMP-9 and 
MMP-12 from purified neutrophils. Data is from single experiment and represent 
neutrophils from group 6-8 corneas. (D) Neutrophil depletion was carried out from day 7 
pi, using anti-Gr-1 mAb (100 µg/mice, intra-peritoneally) as shown. Mice in the control 
group received isotype control antibody. Representative FACS plot shows complete 
depletion of neutrophils from spleen (upper panel) and cornea (lower panel) analyzed at 
day 11 pi. (E) Corneal lysates from normal (N), isotype control antibody treated (IC) and 
neutrophil depleted (Gr-1) from day 11 pi mice, were analyzed by WB for VEGF-A 
(upper panel), sVEGFR-1 (middle panel).  Figure is a representative of two experiments 
and each experiment represent at least 3 corneas. (F) Relative fold change in the 
expression of VEGF-A and MMP-9 mRNA in neutrophil depleted and isotype antibody 
treated mice at day 11 pi as compared to naïve mock infected mice. Figure is a 
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representative of two experiments and each experiment represent at least 4 corneas. 
Ly6G+ neutrophils were sorted from day 11 pi corneas. Cell suspension from 6-8 pooled 
corneas was used for neutrophil purification. Purified neutrophils were analyzed by either 
WB or RTPCR for the expression of VEGF-A. (G) Reducing WB analysis for VEGF-A 
from two different samples S1- Sample 1 and S2-Sample 2 shows the presence of VEGF-
A protein from purified neutrophil samples. Data represent two different experiments and 
each sample represent neutrophils from 6-8 corneas. (H) Agarose gel analysis for β-actin 
(92bp) (lane 2) and VEGF-A (214bp) (lane 4) of cDNA from purified neutrophils. Lane 1 
and 3 are reverse trancriptase negative control for β-actin and VEGF-A respectively.  (I) 
Neutrophil depletion started from day 7 pi and continued until day 13 pi resulted in 
reduced angiogenesis as well as SK lesion severity. Data are representative of a two 
independent experiments (n = 8-10 mice/group). P = 0.0131 (*), P = 0.0068 (**).  
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FIGURE 3.7. SCHEME ILLUSTRATING THE MECHANISM FOR HSV-1 MEDIATED CORNEAL 
ANGIOGENESIS.  
Normal uninfected cornea constitutively secretes large amount of sVEGFR-1 and 
small amounts of VEGF-A. sVEGFR-1 constrains the physiological effect of VEGF-A by 
binding it with very high affinity (Left panel). Early after corneal HSV-1 infection, there 
is sudden increase in the levels of VEGF-A primarily being produced by infected or 
nearby uninfected corneal epithelial cells. However, levels of sVEGFR-1 go down 
mainly due to decreased production of sVEGFR-1 by corneal epithelial cells and also due 
to degradation by MMP-2, MMP7 and MMP9. This in turns leads to more 
physiologically active VEGF-A, which is now free from inhibitory effect of sVEGFR-1. 
This active form of VEGF-A drives the initial angiogenic sprouting early after HSV 
infection (middle panel). During chronic phase of HSK, when HSV-1 is no longer 
detected in the cornea, inflammatory cells particularly neutrophils act as a source of 
VEGF-A and different MMPs. This second wave of VEGF-A and MMPs further 
maintains the angiogenic response by continuous supply of active form of VEGF-A and 
MMPs, which degrades sVEGFR-1. The development of new leaky blood vessels leads 
to the release of more plasma and inflammatory cells in the cornea thus setting the stage 
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SUPPLEMENTAL FIGURE 3.1:  HSV-1 INFECTION OF MK/T-1 CELLS DIFFERENTIALLY 
REGULATES THE EXPRESSION OF SVEGFR-1 AND VEGF-A. 
(A) Uninfected MK/T-1 cells express both VEGF-A (214bp) (lane 3) and 
sVEGFR-1 (358bp) (lane 5) as shown by agarose gel analysis for cDNA. Lane M-
marker, lane 1- β-actin (92bp), lane 2, 4 and 6 are reverse transcriptase negative controls 
for β- actin, VEGF-A and sVEGFR-1. Figure is representative of two independent 
experiments.  (B) MK/T-1 cells were infected with 3 MOI of HSV-KOS. At each time 
point cells were harvested for mRNA extraction. The expression levels of VEGF-A and 
sVEGFR-1 molecule were normalized to β-actin using ΔCt calculation. Quantification of 
VEGF-A and sVEGFR-1 mRNA at different time point shows differential gene 
expression post HSV infection as compared to uninfected cells. Data are expressed as 
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SUPPLEMENTAL FIGURE 3.2.  RSVEGFR-1 TREATMENT POST HSV INFECTION 
DIMINISHES ANGIOGENESIS AND SK LESION SEVERITY.  
WT mice were ocularly infected by corneal scarification with 104 PFU of HSV. 
(A) rsVEGFR-1 or isotype Fc protein were administered subconjunctivally at 5 µg/eye as 
shown.  The extent of angiogenesis and SK lesion severity in the eyes of HSV infected 
mice were quantified in a blinded manner using a scale as described in materials and 
methods. Cumulative scores for angiogenesis and SK lesion severity at day 15 pi. (n = 
17-22 mice/group). Data are a summary of two independent experiments. P = 0.0001 
(***). (B) Mice were sacrifice on day 15 pi and corneas were collected for surface 
staining of eye infiltrating cells. Representative FACS plot for CD31+ cells, Neutrophils 
(CD11b+, Ly6G+ cells) gated on total CD45+ cells and CD4+ T cells showed reduced 
frequencies of respective cell population in the rsVEGFR-1 treated mice as compared to 
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SUPPLEMENTAL FIGURE 3.3.  MMPI TREATMENT REDUCES THE FREQUENCIES CD31+ 
ENDOTHELIAL CELLS, NEUTROPHILS AND CD4+ T CELLS. 
WT mice corneas were scarified and infected with 104 PFU of HSV or mock 
infected with only PBS (naïve control mice). Marimastat, a broad-spectrum MMP 
inhibitor (MMPi) was administered subconjunctivally at 200 ug/mouse preventively (A) 
or therapeutically (B) as shown. Mice in control group received HSV infection with mock 
treatment. Representative FACS plot and total cell numbers per cornea for CD31+ cells, 
Neutrophils (CD11b+, Ly6G+ cells) and CD4+ T cells showed significant reduction in 
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In this chapter “our” and “we” refers to me and co-authors. My contribution in the 
chapter includes (1) Selection of the topic (2) Compiling and interpretation of the 
literature (3) Designing experiments (4) Understanding the literature and interpretation of 
the results (5) Providing comprehensible structure to the chapter (6) Preparation of graphs 
and figures (7) Writing and editing.  
 
Abstract 
 Corneal herpes simplex virus (HSV) infection leads to the development of 
angiogenesis by causing an imbalance between vascular endothelial growth factor 
(VEGF) and its soluble receptor-1 (sVEGFR-1), however the underlying mechanisms are 
poorly understood. Here we demonstrate that IL-17A, a cytokine induced after HSV 
infection shifts the balance between VEGF-A and sVEGFR-1 and thereby promotes 
corneal angiogenesis. Accordingly, HSV infection of mice lacking IL-17 receptor (IL-
17RAKO) and IL-17A neutralization in WT HSV infected mice resulted in significantly 
diminished corneal neovascularization, an outcome of multiple mechanisms. Firstly, IL-
17A through direct and indirect actions promoted corneal VEGF-A levels by corneal 
stromal keratocytes. Secondly, IL-17A enhanced corneal matrix metalloproteinase 
(MMP) -2, -7 and -9 expression that additionally improved VEGF-A bioavailability 
through increased sVEGFR-1 degradation. Additionally, IL-17A potentiated the 
angiogenic response by increased expression of CXCL1/KC and subsequent migration of 
neutrophils in the cornea. Moreover, neutrophils contribute to the imbalance between 
VEGF-A and sVEGFR-1 by acting as a source of VEGF-A as well as MMPs that degrade 
sVEGFR-1.  Collectively, the multiple actions of IL-17A acted to increase VEGF-A and 
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diminish the anti-angiogenic action of the sVEGFR-1. This could mean that targeting IL-




Optimal vision demands corneal transparency so that light transmission proceeds 
to the retina without interruption. Several mechanisms are employed to achieve 
transparency. These include events that suppress angiogenesis and tissue damaging 
inflammatory and immune reactions in the pre-retinal tissues (1-3). The control system 
lacks perfection and breaks down in response to some injurious events. Infection of the 
cornea with herpes simplex virus-1 (HSV) is one such event and this can result in corneal 
blindness (stromal keratitis- SK) after frequent recrudescences from latent infection in the 
trigeminal ganglion (3, 4). The SK lesions, which largely represent T cell orchestrated 
inflammatory reactions set off by the virus (5-7), are one of the commonest infectious 
causes of vision loss in developed countries (3). One prominent feature of SK lesions is 
the establishment of new blood vessels in the normally avascular cornea (3, 8, 9). Most of 
our understanding of the pathogenesis of SK, particularly the role of neovascularization, 
comes from studies of animal models where SK is a regular outcome of primary HSV 
infection of the cornea (5-7). Although several molecules may participate in corneal 
neovascularization, the principal mediator is VEGF-A signaling through the VEGFR-2 
receptor (8, 10). Curiously, VEGF-A is synthesized by the normal cornea, but its 
angiogenic activity is constrained by its binding to an excess of the soluble form of the 
VEGF receptor 1 (sVEGFR-1) that is produced by corneal epithelial cells (2). This 
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situation is often referred as the VEGF trap (2, 11-13). The consequence of HSV ocular 
infection is a change in the concentration balance between VEGF-A and the soluble 
receptor (14), but how this is achieved is not fully understood.  
              Previous studies have established that HSV infection, either directly or 
indirectly, causes the increased production of VEGF-A, but reduces the synthesis 
sVEGFR-1 (8, 14-17). Additionally, the inflammatory reaction induced by HSV includes 
the infiltration of cells that produce enzymes such as MMP-2, -7 and -9 that degrades 
sVEGFR-1, into inactive fragments (14, 18). Since regulation of VEGF levels and 
molecules that influence its signaling represent valuable approach to control pathological 
angiogenesis (3, 8-10, 14, 19), it is important to understand how the multiple molecules 
generated in the inflamed cornea after HSV infection impact on VEGF function. In the 
present report, we focus on the cytokine IL-17A which, as we showed recently 
(unpublished data), is rapidly upregulated in the eye after HSV infection.  Moreover, past 
studies had demonstrated that fibroblasts and monocytes exposed in vitro to IL-17 may 
produce VEGF-A (20-25). Additionally, IL-17 was shown to play a role in mediating 
tumor angiogenesis by causing the proliferation and migration of vascular endothelial 
cells into tissue (26). Little is currently known about the participation of IL-17 in ocular 
angiogenesis, particularly how it might impact on the efficiency of the VEGF-A trap.  
In the present report, we demonstrate that HSV induced IL-17A expression in the 
cornea is a critical factor responsible for changing the balance between VEGF-A and 
sVEGFR-1. HSV infection of mice lacking IL-17A signaling or neutralization of IL-17A 
in WT HSV infected mice showed reduced corneal angiogenic responses. The 
mechanisms for diminished angiogenesis were multiple and included reduced corneal 
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expression of VEGF-A but no effects on sVEGFR-1 levels by HSV infected IL-17RA-/- 
mice when compared to WT counterparts. Additionally, IL-17A induced IL-6 production 
by corneal stromal fibroblasts, and IL-6 in combination with IL-17A acted in concert to 
further up-regulate VEGF-A production. Furthermore, IL-17A directly enhanced MMP-9 
production by corneal fibroblast cells as well as indirectly affected the corneal MMP-2 
and MMP-9 expression after HSV infection. Theses MMPs further increased VEGF-A 
bioavailability through increased sVEGFR-1 degradation. Moreover, IL-17A also 
induced the expression of a neutrophil chemoattractant, CXCL1/KC in the cornea after 
HSV infection. The increased levels of CXCL1/KC in the cornea promoted the migration 
of neutrophils at the site of inflammation, which further affected the balance between 
VEGF-A and sVEGFR-1 by providing an additional source of pre-formed VEGF-A as 
well as sVEGFR-1 degrading MMPs. Taken together our data shows that IL-17A plays a 
central role in regulating ocular angiogenesis and does so at least in part by limiting the 
efficacy of the VEGF trap. 
 
Material and Methods 
Mice, Virus and cell lines. IL-17RA-/- mice on a C57BL/6 background were obtained 
from Amgen (Thousand Oaks, CA). C57BL/6 mice were purchased from Harlan Sprague 
Dawley, Indianapolis, IN. Animals were housed in the animal facilities approved by the 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) at 
The University of Tennessee and all experimental procedures were in complete 
agreement with the Association for research in Vision and Ophthalmology resolution on 
the use of animals in research. HSV-1 RE Tumpey viruse was grown in Vero Cell 
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monolayers (ATCC no. CCL81, American Type Culture Collection). The virus was 
concentrated, titrated, and stored in aliquots at -800 C until use. MK/T-1 cell line 
(Immortalised keratocytes from C57/BL6 mouse corneal stroma) was kindly gifted by Dr. 
Reza Dana, Schepens Eye Research Institute and Department of Ophthalmology, Harvard 
Medical School, Boston MA.  
Corneal HSV Infection and Clinical Scoring. Corneal infections of mice were 
conducted under deep anaesthesia induced by i.p. injection of avertin as previously 
described (8). Mice were scarified on their corneas with 27-gauge needle, and a 3-µl drop 
containing 1×104 PFU of virus was applied to the eye. The eyes were examined on 
different days pi for the development and progression of clinical lesion by slit-lamp 
biomicroscope (Kowa Company, Nagoya, Japan). The progression of SK lesion severity 
and angiogenesis of individually scored mice was recorded. The scoring system was as 
follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or 
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer; 
+5, corneal rupture and necrotizing keratitis. The severity of angiogenesis was recorded 
as described previously (27). According to this system, a grade of 4 for a given quadrant 
of the circle represents a centripetal growth of 1.5 cm towards the corneal center. The 
score of the four quadrants of the eye were then summed to derive the neo vessel index 
(range 0‐16) for each eye at a given time point. 
Sub‐conjunctival Injection. Subconjunctival injections of anti-IL-17 were performed as 
described previously (28). Briefly, subconjunctival injections were done using a 2‐cm, 
32 gauge needle and syringe (Hamilton, Reno, NV) to penetrate the perivascular region 
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of conjunctiva, and the required dose of anti-IL-17 mAb was delivered into 
subconjunctival space. Control mice received isotype mAb. 
IL-17 Neutralization. C57BL/6 mice were ocularly infected and 0.05 mg of anti-IL-17 
was given intraperitoneally (ip) starting from day 7 followed by day 10 and 13 pi. For 
local depletion, 5 µg anti-IL-17 mAb was administered by sub-conjunctival injection 
either startind from day 1 pi followed by day 3 and day 5 pi for earl y depletion or 
starting from day 7 pi followed by day 9, day 11 and day 13 pi for late depletion. 
γδ T cell Depletion. C57BL/6 mice were injected 2 days before infection with 500 µg 
per mouse of anti-mouse γδ TCR mAb (clone UC3-10A6) followed by 250 µg per mouse 
on day of infection.   
Flow Cytometry. Corneas were excised, pooled group wise, and digested with 60 U/ml 
Liberase for 35 minutes at 370C in a humified atmosphere of 5% CO2. After incubation, 
the corneas were disrupted by grinding with a syringe plunger on a cell strainer and a 
single-cell suspension was made in complete RPMI 1640 medium. The single cell 
suspensions obtained from corneas were stained for different cell surface molecules for 
FACS. All steps performed at 40C. Briefly, cell suspension was first blocked with an 
unconjugated anti CD32/CD16 mAb for 30 min in FACS buffer. After washing with 
FACS buffer, samples were incubated with CD45-allophycocyanin (30-F11), CD11b-
PerCP (M1/79), Ly6G-PE (1A8) and CD31-PE (MEC13.3) (All from BD Biosciences-
Pharmingen) for 30 min on ice. Finally, the cells were washed three times and re-
suspended in 1% para-formaldehyde. The stained samples were acquired with a FACS 
Calibur (BD Biosciences) and the data were analyzed using the FlowJo software. 
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Quantitative Real-Time PCR (qRT-PCR). Corneal cells were lysed and total mRNA 
was extracted using TRIzol LS reagent (Invitrogen). Total cDNA was made with 500 ng 
of RNA using oligo(dT) primer. Quantitative PCR was performed using SYBR Green 
PCR Master Mix (Applied Biosystem, Foster City, CA) with iQ5 real-­‐time PCR detection 
ssystme (Bio Rad, Hercules, CA). The expression levels of different molecules were 
normalized to β-­‐actin using ΔCt calculation. Relative expression between control and 
experimental groups were calculated using the 2-­‐ΔΔCt formula. The PCR primers used 
were as follows  
β	  ACTIN-­‐	  For	  5’-­‐TCCGTAAAGAATCTCATGCC-­‐3’,	  Rev	  5'-­‐ATCTTCATCCTCCTAGGAGC-­‐
3'; IFN-­‐Υ	  For	  5’-­‐GGATGCATTCATGAGTATTGC-­‐3’,	  Rev	  5’-­‐GCTTCCTGAGGCTGGATTC-­‐
3’; IL17A	   For	   5’-­‐	   GCTCCAGAAGGCCCTCAG-­‐3’,	   Rev	   5’-­‐	   CTTTCCCTCCGCATTGACA-­‐3’; 
IL6-­‐	   For	   5’-­‐	   CGTGGAAATGAGAAAAGAGTTGTGC-­‐3’,	   Rev	   5’-­‐	  
ATGCTTAGGCATAACGCACTAGGT-­‐3’ TGFβ-­‐For	   5'-­‐	   TTGCTTCAGCTCCACAGAGA-­‐3’,	  
Rev	  5’-­‐	  TGGTTGTAGAGGGCAAGGAC-­‐3’;	  CCL20	  -­‐	  For	  5’-­‐GCCTCTCGTACATACAGACGC-­‐
3’,	  Rev5’-­‐CCAGTTCTGCTTTGGATCAGC-­‐3’.	  
Western blot analysis. The supernatants from lysed corneal cells were quantified using 
BCA protein Assay kit (Thermo scientific, Waltham, MA) using BSA as a standard and 
samples with equal protein concentrations were denatured by boiling in Laemmli buffer. 
Polypeptides were resolved by SDS-PAGE and transferred onto a PVDF membrane. The 
membrane was blocked with 5% BSA in Tris-buffered saline with Tween20 (20 mM Tris 
[pH 7.4], 137 mM NaCl, and 0.1% Tween20) overnight at 40C and probed with specific 
primary and secondary antibodies. Proteins were detected using chemiluminiscent HRP 
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substrate (Millipore, Billerica, MA). The membrane was kept in stripping buffer for 10 
min and re-probed using anti-β-actin antibody. The antibodies used were rat anti 
sVEGFR-1 (141515; R&D Systems), mouse anti-VEGF-A (EE02; Santa Cruz 
Biotechnology, Santa Cruz, CA), mouse anti-β-actin (AC74; Sigma-Aldrich, St Louis 
MO), goat anti rat IgG-HRP (R & D Systems), goat anti-mouse IgG-HRP (Santa Cruz 
Biotechnology) and donkey anti goat IgG-HRP (Santa Cruz Biotechnology). 
Immunofluorescence staining. For immunofluorescence staining, the eyes from naïve 
uninfected mice were enucleated, and snap frozen in OCT compound. Six-micron thick 
sections were cut, air dried, and fixed in acetone-methanol (1:1) at room -20 0C for 10 
min. Sections were blocked with 10% goat serum containing 0.05% Tween20 and 1:200 
dilution of Fc block (Clone 2.42G2; BD Biosciences Pharmingen, San Diego, CA). Rat 
anti-Ly6G (Clone RB6-8C5; eBioscience) was diluted in 1% BSA containing 0.1% 
Triton-X and incubated at room temp for 1 hr. After incubations sections were washed 
several times with PBST and then stained with rabbit anti rat Alexa-488 for 45 min. The 
corneal sections were repeatedly washed with PBST and mounted with mounting media 
containing propidium iodide as a nuclear stain (Vector Laboratories) and visualized under 
a Immunofluorescence microscope.  
ELISA. The pooled corneal samples were homogenized using a tissue homogenizer and 
supernatant was used for analysis. The concentrations of VEGF-A, sVEGFR-1, CXCXL-
1/KC (R & D Systmes) and IL-6 (eBioscience) were measured by using sandwich ELISA 
kits  as per the manufacturer’s instructions. 
Statistics. Student’s t test was performed to determine statistical significance and data are 
expressed as mean ± SEM. 
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Results 
 
Lack of IL-17A receptor signaling diminishes severity of HSV induced corneal 
angiogenesis 
To study the role of IL-17A and IL-17A receptor signaling effects on HSV 
induced corneal angiogenesis, IL-17RA-/- mice were ocularly infected with HSV and the 
severity of angiogenesis was compared with infected control WT mice. At all time points, 
IL-17RA-/- mice showed significantly lesser angiogenesis than WT animals (Fig 4.1A-
B). The onset of visible angiogenic sprouting was delayed, angiogenesis scores were 
lower and more mice had diminished angiogenesis scores in IL-17RA-/- mice as 
compared to their WT counterparts (Fig 4.1A). Additionally, not only the frequency but 
also the severity of angiogenesis (scores of ≥8) was reduced in mice in the IL-17RA-/- 
group (2 of 8 eyes at day 21) compared to WT counterparts (9 of 11 eyes at day 21) (Fig 
4.1B). Analysis by FACS of pooled corneas from IL-17RA-/- and WT mice in each 
group at day15 pi revealed reduced frequencies as well as total numbers of CD31+ cells 
(a marker for blood vessel endothelium) in IL-17RA-/- as compared to WT animals (Fig 
4.1C-E).  
Further evidence that IL-17A signaling was involved in HSV induced corneal 
angiogenesis came from measuring the outcome of neutralizing anti-IL-17 mAb 
treatment of HSV infected WT mice over a period of 15 days. IL-17 neutralization was 
started from day 7 pi when angiogenic sprouting became evident, followed by additional 
treatment on days 10 and 13 pi (Fig 4.2A).  Animals that received the mAb showed a 
significant reduction in peak angiogenesis scores as compared to control isotype treated 
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mice (Fig 4.2B). Moreover, the frequency of severe angiogenesis (scores of ≥8) was 
significantly reduced in animals from the mAb recipients (3 of 8 eyes) as compared to 
isotype Ab recipients (7 of 8 eyes) (Fig 4.2C).  
Interestingly, local sub-conjunctival administration of anti-ILA mAb showed an 
even more profound inhibitory effect on the onset as well as severity of HSV induced 
corneal angiogenesis (Fig 4.2D-G). Corneal samples collected at the end of the 
experiment revealed reduced frequency as well numbers of CD31+ cells in the IL-17A 
neutralized group as compared to isotype mAb recipients (Fig 4.2H-J). Taken together 
these data indicate that mice lacking signaling for IL-17A were more resistant to HSV 
induced corneal angiogenesis indicating that IL-17A plays a critical role in driving the 
neovascularization resulting from HSV infection.  
  
A. IL-17A differentially regulates VEGF-A and sVEGFR-1 expression after HSV 
infection   
To further study the role of IL-17A in HSV induced corneal angiogenesis, the 
levels of VEGF-A and sVEGFR-1 produced by HSV infected corneas was measured by 
ELISA, RT-PCR and WB in both WT and IL-17RA-/- mice at various time points pi. As 
already described, compared to WT, IL-17RA-/- mice showed diminished levels of 
VEGF-A (Fig 4.3A-B), but the level of sVEGFR-1was not reduced and remained 
approximately the same as in uninfected control animals (Fig 4.3 C, D). Additionally, 
when the ratio of total number of sVEGFR-1 molecules per VEGF-A molecule from 
naïve mice was compared with infected animals at varios time points pi, the ratio was 
significantly decreased in WT animals at all days pi, but not in IL-17RAKO mice (Fig 
	   150	  
4.3E). Furthermore, depletion of γδ T cells, which act as an early source of IL-17A, 
resulted into diminished levels of VEGF-A further confirming the role of IL-17A in 
VEGF-A production (Fig 4.3F-G). To further confirm the role of IL-17A in VEGF-A up-
regulation, IL-17A neutralization was carried out either starting from day 1 until day 7 pi 
(Fig 4.3H), or starting from day 7 pi until day 15 pi (Fig 4.3I). Both the depletion 
strategies resulted into reduced VEGF-A mRNA expression (Fig 4.3J) as well as reduced 
VEGF-A protein production (Fig 4.3K).  
Additional in-vitro experiments were performed with an immortalized murine 
corneal stromal fibroblast cell line (MK/T-1 cells) to measure the effect of IL-17A 
stimulation on the production of both VEGF-A and sVEGFR-1. Stimulation with IL-17A 
caused a dose dependent increase of VEGF-A secretion, but had minimal and 
insignificant effects on sVEGFR-1 levels as measured by ELISA (Fig 4.3L-N).  Taken 
together, these in vitro studies also support the idea that the presence of IL-17A could 
shift the balance between VEGF-A to its inhibitory sVEGFR-1, making the VEGF-A trap 
less efficacious.   
 
B. IL-17A induces IL-6 expression and in combination expands production of 
VEGF-A by corneal stromal fibroblasts. 
 One potential mechanism by which IL-17A acts could be to influence the 
expression of other cytokines known to be indirectly involved in angiogenesis such as IL-
6 and IL-1β (3, 16, 20, 23, 24). To evaluate the possibility, levels of corneal IL-6 were 
compared between HSV infected IL-17RA-/- and WT counterparts at various days pi by 
RT-PCR. Corneal samples from IL-17RA-/- mice showed diminished expression of IL-6 
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at all tested days pi (Fig 4.4A). Moreover, local neutralization of IL-17A during early as 
well as late phase of HSV infection (Fig 4.4B) resulted into reduced mRNA expression of 
IL-6 on day 7 and day 15 pi (Fig 4.4C).  Further in-vitro studies were done to study the 
effect of IL-17A on the expression of IL-6/IL-1β and their combined role in the induction 
of VEGF-A by corneal stromal fibroblasts (MK/T-1) cells. IL-17A increased the 
production by MK/T-1 cells of IL-6 in a dose dependent manner, and addition of anti-IL-
17A mAb completely blocked IL-17A induced production of IL-6 (Fig 4.4D-E). 
Interestingly, IL-17A in combination with IL-6 and IL-1β potentiated VEGF-A 
production by corneal stromal fibroblast cells (Fig 4.4 F-H). Taken together, these data 
indicated that IL-17A indirectly promoted the expression of VEGF-A through increased 
expression of pro-angiogenic cytokines such as IL-6. These cytokines independently as 
well as in combination with IL-17A increased the expression of VEGF-A, further 
deviating the balance between VEGF-A and sVEGFR-1. 
 
C. IL-17A drives increased expression of various MMPs responsible for sVEGFR-1 
degradation 
 Another mechanism by which IL-17A signaling could influences angiogenesis 
was via its effect on the expression of different MMP enzymes that degrade sVEGFR-1, 
but not VEGF-A (14, 29, 30), into non-functional fragments. Comparing the corneal 
samples from HSV infected IL-17RAKO and WT mice taken at various days pi, levels of 
MMP-2, MMP-7 and MMP-9 were reduced in IL-17RAKO mice as compared to WT 
(Fig 4.5A-C). Furthermore, neutralization of IL-17A in WT HSV infected mice resulted 
into diminished expression of MMP-2, MMP-7 and MMP-9 when compared to isotype 
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treated animals (Fig 4.5 D-G). Additionally, in vitro experiments with IL-17A stimulated 
MK/T-1 cells also revealed dose dependent increase in MMP-9 mRNA expression as 
measured by RT-PCR (Fig 4.5H). This effect was inhibited by the addition of anti-IL-
17A mAb indicating that it was IL-17A specific. Collectively, these results indicate that 
IL-17A could influence the efficacy of the VEGF-A trap by increasing the synthesis of 
some MMPs that can cause sVEGFR-1 degradation, making more VEGF-A available to 
induce angiogenesis. 
 
C. Additional mechanisms caused by IL-17A affecting efficiency of the VEGF-A 
trap 
Additional consequences of IL-17A induction following HSV infection might 
also contribute indirectly to angiogenesis by increased the synthesis of CXCL1/KC, a 
chemoattractant for neutrophils (22, 23, 25, 31-33). The consequent higher infiltration of 
neutrophils (CD45+CD11b+ Ly6+ cells), act as a source of VEGF-A as well as sVEGFR-1 
degrading MMPs (14, 18, 34). To test this possibility, we measured the levels of 
CXCL1/KC between WT and IL-17RAKO mice at various time points.  At all times 
tested, significantly reduced CXCL1/KC levels were observed in corneas of IL-17RAKO 
mice as compared to WT control mice (Fig 4. 6A-B). The role of IL-17A in CXCL1/KC 
production was further confirmed by the in-vitro stimulation of MK/T-1 cells with 
different concentrations of IL-17A for 24 hr. Unstimulated MK/T-1 cells produced basal 
amounts of CXCL1/KC, but the addition of IL-17A even at very low concentrations to 
the culture media, increased CXCL1/KC production by 4.5 fold (Fig 4.6 C-D). 
Neutralization of IL-17A completely inhibited the CXCL1/KC production by stromal 
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fibroblasts indicating a direct role of IL-17A in the upregulation of CXCL1/KC. 
Moreover, IL-17A was a more potent inducer of CXCL1/KC, when compared to IL-6 
(Fig 4.6 E).  
Further evidence for the role of IL-17A in corneal migration of neutrophils post 
HSV infection came from comparing the corneal infiltrating neutrophils between HSV 
infected WT and IL-17RAKO mice. Accordingly, IL-17RAKO mice had significantly 
reduced frequencies and total cell numbers of neutrophils when compared to WT 
counterparts (Fig 4.6 F-G). Moreover, in-vivo neutralization of IL-17A in WT HSV 
infected mice showed diminished infiltration of neutrophils, further confirming the 
critical role of IL-17A in the migration of these cells to the site of inflammation (Fig 4.6 
H-M). Collectively, these results indicated that the reduced degradation of sVEGFR-1 
and diminished levels of VEGF-A in IL-17RAKO mice as well as post IL-17A 
neutralization in WT mice could be the result of diminished expression of CXCL1/KC 
and consequent reduced infiltration of neutrophils, which indirectly contribute to the 
source of VEGF-A and sVEGFR-1 degrading MMPs. 
 
Discussion 
 The normal eye employs numerous strategies to maintain the corneal transparency 
that is essential for optimal vision. One such inhibitory interaction is between VEGF-A 
and sVEGFR-1. With this VEGF-A trap preventing corneal vascularity reaction. 
However, conditions such as HSV infection of the cornea disrupts the VEGF-A trap 
resulting in corneal neovascularization an essential step in the pathogenesis of SK and 
subsequent vision loss (3, 8, 9). In this report, we investigated how IL-17A induced 
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following HSV infection of the cornea influences the efficacy of the VEGF-A trap. We 
show that IL-17A contributes to changing the balance between VEGF-A and sVEGFR-1 
through multiple mechanisms. Accordingly, animals lacking response to IL-17A 
signaling because of IL-17 receptor knock out or treatment with neutralizing mAb to IL-
17A resulted into significant diminished angiogenesis as compared to WT counterparts. 
The reduced angiogenesis was the consequence of reduced VEGF-A production, but 
retention in levels of sVEGFR-1. Lesser amounts of sVEGFR-1 degrading MMP 
enzymes were produced in the absence of IL-17A signaling as were the production of 
chemokine and cytokines that contributes indirectly to angiogenesis. In vitro results too 
demonstrated that IL-17A stimulated ocular fibroblast produced VEGF-A, but not 
sVEGFR-1 along with neutrophil chemokine, CXCL1/KC, sVEGFR-1 degrading 
enzyme, MMP-9 and proinflammatory cytokine IL-6 and IL-1β, which are indirectly 
involved in angiogenesis. Collectively, our results demonstrated that IL-17A could 
influence the HSV induced corneal angiogenesis by targeting multiple pathways leading 
to the reduce efficacy of the VEGF-A trap. It is conceivable that targeting IL-17A 
mediated effects could prove a better therapeutic option to control of HSV induced 
corneal angiogenesis and lesions of SK. Our overall results are summarized in Fig 4.7, 
showing how HSV induced IL-17A expression orchestrates various critical events 
involved in corneal angiogenesis.  
Since neovascularization is a critical step in the pathogenesis of SK, 
understanding how it is induced in response to HSV infection could reveal new 
approaches for its control. The clue that IL-17A could represent a key event in 
neovascularization came from studies in tumor angiogenesis where IL-17A was shown to 
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act as an inducer of VEGF-A from fibroblast cells (20, 22, 25, 26). Recently, we 
demonstrated that IL-17A is induced early after ocular infection with HSV arising 
initially from γδ T cells that are early invaders of the corneal stroma and spontaneous 
producers of IL-17A (Unpublished data). However, conceivably the earliest source of IL-
17A after HSV infection could be the epithelium itself responding to products released by 
virus infected cells. Virus infected cells may also be the initial source of VEGF-A the 
principal mediator of angiogenesis. However, subsequently the production of VEGF-A 
would seem to depend on stimulation of producer cells by IL-17A. Two lines of evidence 
supported this notion. Firstly we could show a marked reduction in angiogenesis in 
animals unable to respond IL-17A because they lack the IL-17A receptor. Furthermore, 
angiogenesis levels were diminished if infected animals were suppressed with anti-IL-
17A neutralizing mAb. The effect was most evident when the mAb treatment was given 
locally starting on day 7 pi a time when angiogenesis had already begun indicating that 
IL-17A may exerts its predominant influence after the initial phase of neovascularization. 
The overall effect of IL-17A in ocular angiogenesis appeared to be the consequence of 
multiple events. These included the stimulation of VEGF-A production from cells in the 
stroma, as we could model in vitro, as well as the production by stimulated cells of a 
cytokine that attracts neutrophils to the corneal stroma. A second ongoing issue was that 
IL-17 had no stimulatory effect on sVEGFR-1 production, a molecule that can bind to 
VEGF-A and limits its angiogenic activity. More of relevance, IL-17A induced the 
production of MMP-9 from stromal fibroblasts and caused the production of a cytokine s 
that recruits neutrophils into the stroma. Neutrophils also act as a source of VEGF-A as 
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well as several MMP enzymes that could degrade sVEGFR-1. The overall outcome was a 
marked reduction in the efficacy of the VEGF-A trap and enhanced angiogenesis.   
Newly developed blood vessels during pathological angiogenesis are often 
abnormal, lack normal architecture and are leaky thus permitting the escape of pro-
inflammatory cells/molecules into the corneal stroma (3, 19). Prior studies have shown 
the critical role of VEGF-A/VEGFR-2 in mediating HSV induced corneal angiogenesis 
(8-10, 14, 16, 17). However, molecular mechanisms responsible for the VEGF-A 
induction post HSV infection are still unclear. One important aspect of HSV induced 
corneal angiogenesis is the loss of the VEGF-A trap efficacy mainly through increased 
synthesis of VEGF-A and reduced expression of sVEGFR-1 along with its degradation 
by various MMPs (14). Past studies have shown that early after HSV infection, infected 
corneal epithelial or nearby uninfected cells predominantly contribute to the early source 
of VEGF-A (16, 17). Additionally, once virus is cleared from the cornea around day 7 pi 
(3), innate cells such as neutrophils act as an additional source of VEGF-A during the 
clinical stage of SK pathogenesis (3, 14, 18, 34). Although, HSV infection of corneal 
epithelial cells have been shown to induce the expression of VEGF-A, various other 
factors such as IL-6, CpG oligonucleotide could also induce the VEGF-A expression by 
corneal epithelial or stromal fibroblast cells (15, 16). Numerous studies in arthritis and 
tumor systems have indicated the pro-angiogenic role of IL-17A, mainly through 
induction of VEGF-A, MMP-9, IL-1B and IL-6 (20-23, 25, 26).  Since we observed 
increased expression of IL-17A early after HSV infection (unpublished data, Part II), it is 
conceivable that IL-17A could be modulating the expression of VEGF-A in the cornea 
post HSV infection.  In consequence, the reduced levels of VEGF-A in IL-17RA-/- mice 
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and post IL-17 neutralization in WT mice indicated that IL-17A plays a similar role in the 
induction of VEGF-A post corneal HSV infection. Consistent with the findings, in-vitro 
data indicated that corneal stromal fibroblasts could also provide a supplementary source 
of VEGF-A through IL-17A mediated signaling. Since epithelial cells also express IL-
17RA, increased VEGF-A expression post HSV infection could be the combined result of 
IL-17A mediated paracrine expression of VEGF-A by corneal epithelial as well as 
stromal fibroblast cells. However, currently we lack evidence for the IL-17A mediated 
effects on corneal epithelial cell expression of VEGF-A. Further studies using corneal 
epithelial cell line would shed more light on role of IL-17A and the relative contribution 
of epithelial cells to the source of VEGF-A.  
 In addition to increased VEGF-A expression, reduced levels of sVEGFR-1, 
mainly through reduced synthesis along with MMP mediated increased degradation, 
potentiate the VEGF-A mediated effects and subsequent corneal angiogenesis post HSV 
infection (14, 29). Furthermore, increased degradation of sVEGFR-1 post HSV infection 
could also contribute to the source of VEGF-A by releasing pre-formed VEGF-A bound 
to sVEGFR-1 (2, 14). HSV infection drives the increased expression of various MMPs, 
which selectively degrade sVEGFR-1 into biologically non-active form (14, 18), 
contributing to the inefficacy of the VEGF-A trap. Although earlier studies showed that 
HSV infection upregulated the expression of MMPs (14, 18), underlying mechanisms for 
MMPs upregulation are poorly understood. Our study showed that IL-17A orchestrated 
various events following HSV infection. In addition to increased expression of VEGF-A, 
IL-17A also upregulated the expression of MMP-9 by corneal stromal fibroblast cells, 
which through degradation of sVEGFR-1 enhanced the biological activity of VEGF-A. 
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Support for this finding came by observing the levels of various MMPs in the corneas of 
HSV infected IL-17RA-/- mice, which showed significantly diminished expression of 
MMP-7 and -9. Additionally, reduced degradation of sVEGFR-1 from corneal samples of 
IL-17RA-/- mice suggested that IL-17 directly affects the efficacy of the VEGF-A trap 
through the expression of various sVEGFR-1 degrading MMPs. Our findings are in 
accord with the previously published reports where lack of MMP activity post HSV 
infection as observed in MMP-9-/- mice or treatment of HSV infected WT mice with 
broad spectrum MMP inhibitor showed diminished angiogenesis (14, 18). Thus our data 
indicates that increased expression of IL-17A post HSV infection perturbs the balance 
between VEGF-A by directly increasing the expression of VEGF-A as well as MMPs, 
which participate in the degradation of sVEGFR-1. 
 Another important aspect of IL-17A mediated signaling is the upregulation of 
CXCL1/KC, a chemoattractant for neutrophils and subsequent neutrophil mediated 
effects in the promotion of corneal angiogenesis (22, 23, 25, 31-33). Neutrophils are the 
predominant cells that infiltrate the cornea during all stages of SK pathogenesis (14). 
Although, neutrophils initially play a protective role in virus clearance (35), subsequently 
they contribute to the corneal tissue damage and angiogenesis by providing an additional 
source of VEGF-A, various oxy-radicals as well as MMPs (3, 14, 18).  IL-17A through 
its myriad effects on epithelial and stromal fibroblast cells were also shown to increase 
the expression of neutrophil chemoattractant CXCL1/KC and subsequent infiltration of 
neutrophils at the site of inflammation (22, 23, 25, 31-33). Since, earlier reports from our 
lab showed that HSV infection induces IL-17A expression (unpublished data) as well as 
migration of the neutrophils in the cornea (3, 14, 36), it is conceivable that IL-17A may 
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contribute to the neutrophil influx by increasing the expression of CXCL1/KC by stromal 
fibroblasts. Although, this initial innate immune response early after HSV infection is 
essential for viral clearance, subsequent continued migration of neutrophils could set up a 
stage for the development of complex SK pathogenesis. Indeed our data showing the 
reduced levels of CXCL1/KC, subsequent diminished infiltration of neutrophils along 
with reduced angiogenesis in mice lacking IL-17RA signaling and after IL-17 
neutralization in WT mice confirmed the previous findings as well as supported the 
notion that neutrophil infiltration during clinical stages of SK could promote corneal 
angiogenesis. Furthermore, our data also indicated the critical link between HSV 
infection and migration of neutrophils through IL-17A mediated increased expression of 
CXCL1/KC by corneal stromal fibroblast cells. The diminished levels of CXCL1/KC in 
HSV infected IL-17RA-/- mice as well as post IL-17 neutralization indicated the 
important role of IL-17A signaling in promoting neutrophil infiltration at the site of 
inflammation. Additionally, stimulation of corneal stromal fibroblast with IL-17A 
showed significant upregulation of CXCL1/KC even at very low concentration 
confirming the role of IL-17A in the induction of CXCL1/KC. Moreover, IL-17A was 
found to be a more potent inducer of CXCL1/KC as compared to other known factors 
such as IL-6 (16, 37).  An important aspect of this finding is the effect of IL-17A on the 
efficacy of the VEGF-A trap. It is important to note that IL-17A through increased 
expression of CXCL1/KC contributes indirectly to the source of VEGF-A and sVEGFR-
1 degrading enzymes by promoting the migration of neutrophils (3, 14, 18). In addition, 
IL-17A also promoted the expression of other pro-inflammatory cytokines such as IL-1B 
and IL-6, which were shown to exert angiogenic effects in HSV induced corneal 
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angiogenesis (16, 38-40). Previous studies have shown the important role of IL-17A 
signaling in the stabilization and increased mRNA expression of various pro-
inflammatory cytokines and chemokines (22, 23, 33). Accordingly, we found 
significantly diminished expression of IL-1B, IL-6 and TNF-A in mice lacking IL-17A 
signaling, so confirming earlier findings. Furthermore, IL-6 has been shown to play an 
important role in HSV induced corneal angiogenesis, as it promotes the paracrine 
expression of VEGF-A by corneal epithelial cells (16). In accord with previously 
published reports, our in vitro data showed that IL-17A stimulation of MK/T-1 cells 
upregulated the expression of IL-6 and IL-1B. Interestingly, we observed the increased 
expression of VEGF-A by MK/T-1 cells when cells were stimulated with IL-17A in the 
presence of IL-6 and IL-1B.  These results demonstrated that IL-17A could serve as a 
critical mediator of various key events responsible for HSV induced corneal 
neovascularization. 
 In summary, this study identifies new functions of IL-17A responsible for HSV 
induced corneal angiogenesis. It is conceivable that IL-17A through multiple mechanisms 
shifts the balance between VEGF-A and sVEGFR-1 affecting the efficacy of VEGF-A 
trap. Mechanisms for this imbalance were numerous which included direct increased 
expression of VEGF-A, sVEGFR-1 degrading MMPs, IL-6, IL-1B and neutrophil 
chemoattractant. The net effect of IL-17A mediated signals was to increase the levels of 
VEGF-A and reduce the synthesis of sVEGFR-1 along with increased MMP mediated 
degradation of pre-formed sVEGFR-1 molecules. This degradation of sVEGFR-1 might 
also contribute to the source of VEGF-A by being released from its bond to sVEGFR-1 in 
the VEGF-A trap. In addition to direct increased expression of VEGF-A, IL-17 mediated 
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increased expression of IL-6 and IL-1B potentiated the expression of VEGF-A by corneal 
fibroblasts through combined action of all three cytokines. Moreover, IL-17A also 
indirectly contributed to the source of VEGF-A through the increased expression of 
CXCL1/KC followed by increased migration of neutrophils, which further bring the pre-
formed VEGF-A as well as various sVEGFR-1 degrading MMPs at the site of 
inflammation. Since IL-17A signaling controls almost all events in affecting the efficacy 
of the VEGF-A trap, it would seem logical to develop therapies targeting IL-17A 
mediated effects to control corneal angiogenesis and SK immunopathology, an important 
cause of human blindness. 
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FIGURE 4.1. IL-17RA KO DISPLAY DIMINISHED HSV INDUCED CORNEAL 
ANGIOGENESIS. 
To compare the development and progression of corneal angiogenesis, WT and 
IL-17RA KO mice were infected with 1×104 PFU of HSV by corneal scarification. (A) 
The development of new blood vessels in normally avascular cornea was assessed on day 
8, 11, 15 and 21 PI. (B) Corneal Angiogenesis score of individual mice on day 21 PI. 
Data represents means ± SEM (n= 8 to 12 mice per group from two independent 
experiments; *P<0.03, ***P=0.0003). (C-E) Mice were sacrificed on day 15 PI and 
corneas were pooled group wise for flow cytometry analysis. (C) Representative FACS 
plots for corneal CD31+ endothelial cells between WT and IL-17RA KO mice. (D-E) Bar 
graphs show reduced CD31+ endothelial cell frequencies (D) as well as reduced total cell 
numbers per cornea (E) from IL-17RA KO mice group as compared to WT.  Data 
represents mean ± SEM from two independent experiments (n= 5 for WT and 6 for IL-










	   172	  
 
 
	   173	  
FIGURE 4.2. SYSTEMIC AND LOCAL IL-17A NEUTRALIZATION REDUCES SEVERITY OF 
HSV INDUCED CORNEAL NEOVASCULARIAZTION.  
WT mice were infected with 1×104 PFU of HSV by corneal scarification. (A) For 
systemic IL-17A neutralization, animals were injected intraperitoneally with 50 µg anti-
IL-17A or control IgG1 mAb as indicated. (B) The development of new blood vessels in 
normally avascular cornea was assessed on day 8, 11 and 15 PI. (C) Corneal 
Angiogenesis score of individual mice on day 15 PI. Data represents means ± SEM (n= 8 
corneas per group from two independent experiments; **P=0.0015). (D) For local IL-
17A neutralization, mice were injected sub-conjunctivally with 5 µg of anti-IL-17A or 
control IgG1 mAb as indicated. (E) The development of response in normally avascular 
cornea was assessed on day 8, 11 and 15 PI. (F) Corneal angiogenesis score of individual 
mice on day 15 PI. Data represents means ± SEM (n= 8 corneas per group from two 
independent experiments; **P=0.0003). (G) Representative eye photograph of naïve 
uninfected, local isotype mAb or anti-IL-17A mAb treated mice on day 15 PI. In 
uninfected mice, cornea is clear and devoid of any blood vessels (left panel). By day 15 
PI, new blood vessel development reaches to the center of the cornea in isotype mAb 
treated mice (middle panel), but only halfway in anti-IL-17A treated mice (right panel) as 
indicated by white arrows. This panel is representative of two independent experiments 
with 8 eyes per group. (H-J) Mice from local IL-17A neutralization groups were 
sacrificed on day 15 PI and corneas were pooled group wise for flow cytometry analysis. 
(H) Representative FACS plots for corneal CD31+ endothelial cells between isotype mAb 
and anti-IL-17A mAb treated mice. (I-J) Bar graphs show reduced CD31+ endothelial cell 
frequencies (I) as well as reduced total cell numbers per cornea (J) from anti-IL-17A 
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treated group as compared to isotype treated group.  Data represents mean ± SEM from 
two independent experiments (n= 4 and each sample is representative of two corneas). 
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FIGURE 4.3. IL-17A DIFFERENTIALLY REGULATES THE CORNEAL VEGF-A AND 
SVEGFR-1 EXPRESSION.  
WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or 
mock infected with only PBS by corneal scarification. (A) VEGF-A mRNA expression 
was examined and compared between WT and IL-17RAKO mice by quantitative real-
time PCR (qRT-PCR). VEGF-A mRNA levels in mock-infected mice were set to 1 and 
used for relative fold up-regulation at various days PI. Data represents means + SEM 
from two independent experiments (n=2 and each sample is representative of 8 corneas). 
(B) Corneal VEGF-A protein levels were analyzed from WT and IL-17RAKO mice at 
indicated time points. Data show mean values + SEM from three different independent 
experiments (n=3 and each sample is representative of 8 corneas). (C) sVEGFR-1 mRNA 
expression was examined and compared between WT and IL-17RAKO mice by 
quantitative real-time PCR (qRT-PCR). sVEGFR-1 mRNA levels in mock-infected mice 
were set to 1 and used for relative fold change at various days PI. Data represents means 
+ SEM from two independent experiments (n=2 and each sample is representative of 8 
corneas). (D) Corneal sVEGFR-1 protein levels were analyzed from WT and IL-
17RAKO mice at day 7 PI. Data show mean values + SEM from three different 
independent experiments (n=3 and each sample is representative of 8 corneas). (E) Ratio 
of total number of sVEGFR-1 molecules per VEGF-A molecule from naïve (D0) and 
infected corneas at different days PI were compared between WT and IL-17RAKO mice. 
Ratios were calculated. The total number of molecules for sVEGFR-1 and VEGF-A were 
calculated using protein quantities obtained by ELISA and multiplying it with molecular 
weight respective protein and Avogadro’s number. Data show mean values + SEM from 
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three different independent experiments (n=3 and each sample is representative of 8 
corneas). (F) gamma delta T cell depletion was carried out using anti-gamma delta TCR 
antibody (500 ug per mice) as indicated. (G) Corneal VEGF-A protein levels were 
analyzed and compared between isotype and anti-gamma delta TCR mAb treated mice at 
day 2 PI. Data show mean values + SEM from two different independent experiments 
(n=2 and each sample is representative of 8 corneas).  Local neutralization of IL-17A was 
carried out using anti-IL-17A mAb by sub-conjunctival injection during early (H) and 
late (I) stages of HSV infection as indicated. (J) VEGF-A mRNA expression was 
examined and compared between isotype and anti-IL-17A mAb treated mice by 
quantitative real-time PCR (qRT-PCR). VEGF-A mRNA levels in mock-infected mice 
were set to 1 and used for relative fold up-regulation at day 7 PI. Data represents means + 
SEM from two independent experiments (n=2 and each sample is representative of 8 
corneas). (K) Corneal VEGF-A protein levels were analyzed and compared between 
isotype and anti-IL-17A mAb treated mice at day 7 PI. Data show mean values + SEM 
from two different independent experiments (n=2. Each sample consisted of 8-pooled 
corneas). (M-O) MK/T-1 cells (Corneal stromal keratocytes) were stimulated under 
different concentrations of IL-17 in the presence or absence of anti-IL-17A mAb for 24 
hrs. Supernatants were collected for VEGF-A protein estimation by ELISA and cells 
were collected and pooled for analysis of VEGF-A and sVEGFR-1 mRNA expression by 
qRT-PCR. The mRNA levels in control media were set to 1 and used for relative fold up-
regulation at various days PI. (L) IL-17A stimulated VEGF-A production by MK/T-1 
cells in a dose dependent manner. Data represents means + SEM from two independent 
experiments (n=6). Relative fold change in VEGF-A (M) and sVEGFR-1 (N) mRNA 
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expression as compared to control media. Data represents means + SEM from two 
independent experiments (n=2 and each sample is representative of pooled cells from 3 
different wells).  
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FIGURE 4.4. IL-17A STIMULATES IL-6 PRODUCTION BY CORNEAL STROMAL 
FIBROBLAST CELLS AND BOTH THE CYTOKINES FURTHER STIMULATE VEGF-A 
PRODUCTION.  
WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or 
mock infected with only PBS by corneal scarification. (A) IL-6 mRNA expression was 
examined and compared between WT and IL-17RAKO mice by qRT-PCR. (B) Local 
neutralization of IL-17A was carried out using anti-IL-17A mAb by sub-conjunctival 
injection during early () and late () stages of HSV infection as indicated. (C) IL-6 mRNA 
expression was examined and compared between isotype and anti-IL-17A mAb treated 
mice by quantitative real-time PCR (qRT-PCR). IL-6 mRNA levels in mock-infected 
mice were set to 1 and used for relative fold up-regulation at various days PI. Data 
represents means + SEM from two independent experiments (n=2 and each sample is 
representative of 8 corneas). MK/T-1 cells (Corneal stromal keratocytes) were stimulated 
under different concentrations of IL-17 in the presence or absence of anti-IL-17A mAb 
for 24 hrs. Supernatants were collected for IL-6 protein estimation by ELISA and cells 
were collected and pooled for analysis of IL-6 mRNA expression by qRT-PCR. () 
Relative fold change in IL-6 mRNA expression as compared to control media. Data 
represents means + SEM from two independent experiments (n=2 and each sample is 
representative of pooled cells from 3 different wells). The mRNA levels in control media 
were set to 1 and used to relative fold change in mRNA expression. () IL-17A stimulated 
IL-6 production by MK/T-1 cells in a dose dependent manner. Data represents means + 
SEM from two independent experiments (n=6). (N) MK/T-1 cells (Corneal stromal 
keratocytes) were stimulated under different concentrations of IL-17A and IL-6 for 24 
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hrs. Supernatants were collected for VEGF-A protein estimation by ELISA. VEGF-A 
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FIGURE 4.5. IL-17A PROMOTES MMP-2, -7 AND -9 EXPRESSION AND AFFECTS VEGF-A 
BIOAVAILABILITY THROUGH SVEGFR-1 DEGRADATION.  
WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or 
mock infected with only PBS by corneal scarification. (A) MMP-2, (B) MMP-7 and (C) 
MMP-9 mRNA expression were examined and compared between WT and IL-17RAKO 
mice by qRT-PCR. (D) Local neutralization of IL-17A was carried out using anti-IL-17A 
mAb by sub-conjunctival injection during early and later stages of HSV infection as 
indicated. (E) MMP-2, (F) MMP-7 and (G) MMP-9 mRNA expression were examined 
and compared between isotype and anti-IL-17A mAb treated mice by quantitative real-
time PCR (qRT-PCR). MMP-2, -7 and -9 mRNA levels in mock-infected mice were set 
to 1 and used for relative fold up-regulation at various days PI. Data represents means + 
SEM from two independent experiments (n=2 and each sample is representative of 8 
corneas). (H) MK/T-1 cells were stimulated under different concentrations of IL-17 in the 
presence or absence of anti-IL-17A mAb for 24 hrs. Cells were collected and pooled for 
analysis of MMP-9 mRNA expression by qRT-PCR. () Relative fold change in MMP-9 
mRNA expression as compared to control media. Data represents means + SEM from 
two independent experiments (n=2 and each sample is representative of pooled cells from 
3 different wells). The mRNA levels in control media were set to 1 and used to relative 
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FIGURE 4.6. IL-17A PROMOTES NEUTROPHIL INFILTRATION IN THE CORNEA AFTER 
HSV INFECTION THROUGH CXCL1/KC INDUCTION. 
WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or 
mock infected with only PBS by corneal scarification. (A) CXCL1/KC mRNA 
expression was examined and compared between WT and IL-17RAKO mice by 
quantitative real-time PCR (qRT-PCR). CXCL1/KC mRNA levels in mock-infected mice 
were set to 1 and used for relative fold up-regulation at various days PI. Data represents 
means + SEM from two independent experiments (n=2 and each sample is representative 
of 8 corneas). (B) Corneal CXCL1/KC protein levels were analyzed from WT and IL-
17RAKO mice at indicated time points. Data show mean values + SEM from three 
different independent experiments (n=3 and each sample is representative of 8 corneas). 
MK/T-1 cells (Corneal stromal keratocytes) were stimulated under different 
concentrations of IL-17 in the presence or absence of anti-IL-17A mAb for 24 hrs. 
Supernatants were collected for VEGF-A protein estimation by ELISA and cells were 
collected and pooled for analysis of VEGF-A and sVEGFR-1 mRNA expression by qRT-
PCR. The mRNA levels in control media were set to 1 and used for relative fold up-
regulation at various days PI. (C) IL-17A stimulated CXCL1/KC production by MK/T-1 
cells in a dose dependent manner as analyzed by qRT-PCR (top) and ELISA (bottom). 
(D) IL-17A was more potent inducer of CXCL1/KC as compared to IL-6. Data represents 
means + SEM from two independent experiments (n=6). (N) HSV infected WT and IL-
17RAKO Mice were sacrificed on day 1, 2 and 15 PI and corneas were pooled group 
wise for flow cytometry analysis. (E) Representative FACS plots for corneal CD45+ 
CD11b+ Ly6G+ neutrophils between WT and IL-17RA KO mice. (F) Bar graphs show 
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reduced CD45+ CD11b+ Ly6G+ neutrophil numbers per cornea from IL-17RA KO mice 
group as compared to WT.  (G) Local neutralization of IL-17A was carried out using 
anti-IL-17A mAb by sub-conjunctival injection during early (left panel) and late (right 
panel) stages of HSV infection as indicated. (H) CXCL1/KC mRNA expression was 
examined and compared between isotype and anti-IL-17A mAb treated mice by 
quantitative real-time PCR (qRT-PCR). CXCL1/KC mRNA levels in mock-infected mice 
were set to 1 and used for relative fold up-regulation at various days PI. Data represents 
means + SEM from two independent experiments (n=2 and each sample is representative 
of 8 corneas). Mice from local IL-17A neutralization groups were sacrificed on day 15 PI 
and corneas were pooled group wise for flow cytometry analysis. (I) Representative 
FACS plots for corneal CD45+ CD11b+ Ly6G+ neutrophils between isotype mAb and 
anti-IL-17A mAb treated mice. (J) Bar graphs show reduced total CD45+ CD11b+ Ly6G+ 
neutrophils numbers per cornea from anti-IL-17A treated group as compared to isotype 
treated group. (Data is representative of one experiment from 4-pooled corneas). Corneal 
sections from HSV infected corneas of isotype and anti-IL-17A mAb treated mice were 
analyzed by immunofluorescence microscopy with antibody specific for Ly6G (green). 
Sections were counterstained with propidium idodide (red) for nuclear staining. Images 
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FIGURE 4.7. SCHEME DEPICTING VARIOUS CRITICAL EVENTS ORCHESTRATED BY IL-
17A AFTER HSV INFECTION IN CAUSING CORNEAL ANGIOGENESIS. 
(A) Model proposing the critical role of IL-17A in the deviation of physiological balance 
between VEGF-A and sVEGFR-1 after HSV infection. (B) Mechanisms by which IL-
17A promotes corneal angiogenesis after HSV infection. Normally, naïve uninfected 
cornea constitutively secretes large amounts of sVEGFR-1 and small amounts of VEGF-
A. This leads to a perfect physiological balance between these two molecules, sVEGFR-1 
counteracting angiogenic properties of VEGF-A. The net result is the absence of any 
blood vessels in normally uninfected corneas (left panel). However, early after HSV 
infection there is increased expression of IL-17A in the cornea, which is mainly 
contributed by early innate cells such as γδ T cells. The increased levels of IL-17A then 
further contributes to the increased VEGF-A expression by direct stimulation of corneal 
stromal fibroblast cells as well as indirectly through increased production of IL-6 which 
in turn in combination with IL-17A further promotes VEGF-A production. Moreover, 
HSV infection of corneal epithelial cells as well as IL-17A mediated signaling also 
downregulates sVEGFR-1 expression in the cornea. In addition to reduced expression of 
sVEGFR-1, IL-17A also promotes expression of MMP-9, which further affects the 
VEGF-A bioavailability by increased sVEGFR-1 degradation. This in turn leads to more 
physiologically active VEGF-A, which is free from inhibitory actions of sVEGFR-1. This 
free VEGF-A drives the initial angiogenic sprouting early after HSV infection (middle 
panel).  During later stages of SK, when replicating virus is cleared off from the cornea, 
IL-17A also promotes the CXCL1/KC expression, which promotes the migration of 
neutrophils in the inflamed cornea. These neutrophils act as an additional source of pre-
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formed VEGF-A as well as MMPs that contribute to sVEGFR-1 degradation. These 
events in addition to direct stimulatory effects of IL-17A on VEGF-A, IL-6 and MMP-9 
production, further deviates the balance between VEGF-A and sVEGF-1 and leads to the 
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